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Abstract
Cancer is a disease caused by mutations in normal cells. According to the National
Cancer Institute, in 2016, an estimated 1.6 million people were diagnosed and approximately 0.5 million people died from the disease in the United States. There are
many factors that shape cancer at the cellular and organismal level, including genetic,
immunological, and environmental components. In this thesis, we show how mathematical modeling can be used to provide insight into some of the key mechanisms
underlying cancer dynamics. First, we use mathematical modeling to investigate optimal homeostatic cell renewal in tissues such as the small intestine with an emphasis
on division patterns and tissue architecture. We find that the division patterns that
delay the accumulation of mutations are strictly associated with the population sizes
of the tissue. In particular, patterns with long chains of differentiation delay the
time to observe a second-hit mutant, which is important given that for many cancers two mutations are enough to initiate a tumor. We also investigated homeostatic
cell renewal under a selective pressure and find that hierarchically organized tissues
act as suppressors of selection; we find that an architecture with a small number
of stem cells and larger pools of transit amplifying cells and mature differentiated

v

cells, together with long chains of differentiation, form a robust evolutionary strategy
to delay the time to observe a second-hit mutant when mutations acquire a fitness
advantage or disadvantage. We also formulate a model of the immune response to
cancer in the presence of costimulatory and inhibitory signals. We demonstrate that
the coordination of such signals is crucial to initiate an effective immune response,
and while immunotherapy has become a promising cancer treatment over the past
decade, these results offer some explanations for why it can fail.
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Chapter 1
Introduction
Cancer is a major public health burden. According to the National Cancer Institute
(NCI), in 2016, an estimated 1.6 million people were diagnosed and approximately
0.5 million people died from the disease in the United States. Cancer is produced by
mutations in healthy cells. Normally, when cells become old or damaged, they die and
are replaced by new cells, so that the tissue maintains its functionality. When cancer
arises, cells proliferate uncontrolled, and eventually form tumors. Several factors at
the organismal and cellular level can influence the development of cancer. Genetic,
immunological and environmental components can all greatly influence cancer dynamics. In this thesis, we use mathematical modeling to gain insight into some of the
mechanisms that play a crucial role in cancer dynamics.
This thesis consists of 5 chapters. In Chapters 2, 3, and 4, we develop the topics
that form individual manuscripts, and in chapter 5, we present some general conclusions. In chapter 2 we study homeostatic cell renewal in hierarchically organized
tissues such as the colon, the skin and the haematopoietic system, among others. In
the bottom of the hierarchy, there are a small number of stem cells (SCs), which have
almost an infinite replicative capacity. In intermediate positions of the hierarchy are
transit amplifying cells (TACs), which have a limited replicative capacity, and in the
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top of the hierarchy are mature differentiated cells, which are constantly discarded
and replaced to keep the tissue at constant numbers. This process of cell renewal
triggers cascades or chains of differentiations that can greatly influence cancer dynamics. We propose a compartmental model of homeostatic cell renewal through a
system of differential equations that predicts the expected number of mutants in each
compartment of the hierarchy. We use the accumulation of one-hit mutants and the
time to observe a second-hit mutant as measures for cancer risk. We focus on two key
variables: the proliferation patterns and tissue architecture. Overall, we find that if
the optimization task is to reduce the accumulation of one-hit mutants, in the long
run, short chains of differentiation are better; on the other hand, if the optimization
task is to delay the time to observe a second-hit, long chains of differentiation are
preferred. A non-intuitive finding is that an architecture with larger populations in
more primitive compartments delays the accumulation of mutations. The derivation
of the ODEs was carried out by Dr. Natalia Komarova, while I performed most of
the numerical experiments in this chapter under the guidance of Dr. Komarova and
Dr. Helen Wearing.
In chapter 3, we extend the model proposed in chapter 2 by assigning a fitness
advantage/disadvantage to mutants. In chapter 2 we assume that mutations are
neutral, even though when cells divide it is very likely that they acquire a fitness
advantage or disadvantage. It is widely accepted that tissues evolve to minimize
cancer risk. The hierarchical organization of most tissues, the proliferation patterns
for self-renewal, slow division rates, and the type of cell division are examples of how
tissues attempt to minimize cancer risk [1–8]. In this context, the question is whether
the tissues act as suppressors or amplifiers of selection, and under what conditions
proliferation patterns and tissue architecture act as optimal evolutionary strategies
to delay the accumulation of advantageous and disadvantageous mutants. We find
that hierarchically organized tissues are suppressors of selection; in addition, we find
that an increasing architecture (which has a small number of stem cells and larger
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number of mature cells) and long chains of differentiation, are a robust strategy to
delay the time to observe a second-hit mutant, which can be translated into a lower
risk of cancer.
In chapter 4, we model an immune response to cancer. In the last decade, immunotherapy, a treatment that uses the body’s own immune system to attack cancer
cells, has become a promising treatment to fight cancer. Despite its relative success,
there are many factors that can lead to failure. In order to initiate an immune response, T cells need to receive antigen which is carried out by Antigen Presenting
Cells (APCs), typically dendritic cells, and later, a costimulatory signal is activated
so that T cells are ready to kill cancer cells. After activation of T cells, immune
checkpoints (inhibitory signals) are activated which downregulate T cells. We propose a model described by a set of nonlinear differential equations that allows us
to explore different types of immunotherapy treatments, and most importantly, we
investigate scenarios under which immunotherapy can fail or succeed. Overall, if the
inhibitory pathways are not successfully blocked, an immune response might not be
sustained despite high rates of antigen presentation. In particular, if the immune
checkpoints that activate after antigen presentation/reception are not blocked, stimulation of antigen presentation is no longer effective, indicating why treatments that
stimulate antigen reception signaling could fail.
In conclusion, we use mathematical modeling to study homeostatic cell renewal
that gives us a broader understanding of the role of tissue architecture, division patterns and selection, which are key factors that shape cancer dynamics in hierarchically
organized tissues. We also propose a model of an immune response to cancer, which
offers explanations of why some immunotherapy treatments can fail when the immune
checkpoints are activated, despite large rates of antigen presentation.
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Chapter 2
Optimal homeostatic cell renewal

2.1

Introduction

Many tissues in complex organisms are hierarchically organized, such as the human
colon, the small intestine, the skin, and the haematopoietic system. Hierarchically
organized tissues are renewed constantly by means of a balance of cell deaths and
cell divisions. Understanding the mechanisms that regulate cell proliferation and
differentiation patterns is key to explaining the robust nature of homeostasis [4].
Because of the imminent risk of mutation acquisition, tissue organization also plays
an important role in preventing cancer [5–7, 9–13].
At the root of hierarchically organized tissues are a small number of stem cells
(SCs), capable of both self renewal and differentiation into more specialized cells [14].
Downstream from SCs there are intermediate cells of increasing degrees of maturity,
which can undergo a certain number of divisions. Finally, there are fully mature
differentiated cells, which perform their function and are discarded and replenished
through divisions of less differentiated cells. For instance, evidence suggests that
on or near the bottom of the colon crypts and the small intestine crypts, there are
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Figure 2.1: Schematics showing key concepts of the paper. (a) Two types of symmetric
divisions: proliferations and differentiations. Each circle represents a cell, and i
denotes the ith compartment, while i+1 denotes the (i+1)th compartment. Panels (b)
and (c) demonstrate the division chains that replenish 8 differentiated cells eliminated
from the top compartment. Dead cells are denoted by X’s and arrows show divisions.
Cells are arranged in horizontal layers corresponding to compartments. Only the
dividing cells are shown (for example, there may be more than 4 cells in the second
to top compartment in panel (b)). In (b), the dead cells are replaced by a longer
division tree, and in (c) by four shorter division trees.
between 4 − 6 SCs [15–17], and the remaining compartments are composed of transit
amplifying cells (TACs) and finally mature differentiated cells that are discarded, so
that the entire crypt is renewed every 2 − 7 days [18]. A similar situation occurs in
the haematopoietic system, where a stem cell pool of about 400 cells is required to
replenish a daily bone marrow output of about 3.5 × 1011 cells [19].
Stem cells are thought to be capable of symmetric or asymmetric divisions. Asymmetric divisions of a stem cell result in one daughter cell that is a stem cell and the
other daughter cell that is a more differentiated cell. Symmetric divisions result in
two identical daughter cells. The two types of symmetric divisions are illustrated in
figure 2.1(a) in a more general context: differentiation divisions result in two offspring
that are both more differentiated than the dividing cell, and proliferation divisions
result in two offspring whose differentiation status is identical to that of the parent.
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Because experiments to track cell divisions and mutations are in general difficult,
or not feasible in some hierarchically organized tissues, mathematical models have
been used to understand cellular dynamics or homeostasis and mutations. In particular, the origin and development of colorectal cancer have been extensively studied. It
has been demonstrated theoretically that mutations leading to colorectal cancer can
originate in either the stem cell compartment or TACs [5, 9, 11, 20]. Computational
models, such as virtual crypts, have helped to understand the process of self renewal
in hierarchically organized tissues, for instance the organization of the colon [21–24].
Several studies have investigated tissue architecture with the goal of understanding
its utility in protection against mutation accumulation. Traulsen, Werner and colleagues used mathematical models to study mutations in the haematopoietic system,
and found theoretical evidence that tissue architecture and the process of self renewal
were a protection mechanism against cancer [12, 13, 19, 25]. Rodriguez-Brenes et al.
[6] proposed that an optimal tissue architecture that minimized the replication capacity of cells was one where the less differentiated cells had a larger rate of self-renewal.
Shahriyari and Komarova [7] showed that having symmetric stem cell divisions (proliferations and differentiations) rather than asymmetric stem cell divisions minimized
the risk of two-hit mutant generation. Dingli et al. [3] considered the question of
mutation generation by stem cells and found that mutations that increased the probability of asymmetric replication could lead to rapid expansion of mutant stem cells
in the absence of a selective fitness advantage. Pepper et al. [26] examined a tissue
undergoing serial differentiation patterns originating with self-renewing somatic stem
cells, continuing with several TACs differentiations, and showed that such patterns
lowered the rate of somatic evolution. Paper [27] emphasizes the importance of spatial
considerations in the modeling of stem cell hierarchies and division patterns.
Despite significant progress reported in the literature, there are still plenty of unanswered questions regarding tissue renewal and cancer development in hierarchically
organized tissues. Particularly, the optimal mechanisms of self renewal and prolifera-
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tion to maintain homeostasis is a crucial process which is far from being understood.
To illustrate some of the questions we are interested in solving, consider a hierarchical
tissue (such as the colon) where symmetric divisions are prevalent [28–31]. When mature differentiated cells are discarded, cells from the upstream compartment divide to
replace the eliminated cells. This gives rise to a chain of differentiations, because the
cells that differentiated and migrated from the upstream compartment also need to
be replaced, in order to keep the tissue at homeostasis. Figure 2.1(b,c) schematically
illustrates two opposite trends. Both panels depict 8 mature cells that are eliminated.
These cells are replenished by 4 differentiation events, whereby cells from the neighboring compartment differentiate and migrate downstream to replace the dead cells.
In figure 2.1(b), the 4 cells are, in turn, replenished by two differentiation events
from the previous layer (representing a compartment in the hierarchy), leaving two
cells to be replaced. This is done by a single differentiation event from the last layer,
and the remaining cell is then replaced by a proliferation event from the same layer.
These processes comprise a differentiation cascade, or a differentiation chain, which
in this case included differentiation events in 3 consecutive compartments. A different
scenario is shown in figure 2.1(c) where the 4 cells that differentiated and migrated
from the second to top layer are all replaced by proliferation divisions of cells in the
same layer. In this case we have 4 shorter differentiation chains which only include
differentiation events in one compartment. As will be shown, a range of intermediate
scenarios is possible.
Biologically, differentiation chains are shaped by a system of feedback loops determined by signals altering proliferation, differentiation, apoptosis, migration, and
adhesion in both the stem cell compartment and the transit amplifying cells [4, 6, 32].
The proliferation and differentiation activity is a well controlled system to guarantee
tissue homeostasis in hierarchically organized tissues, thus, changes in proliferation
and differentiation patterns might be associated with an increased risk of cancer development, as found, for example, by Merrit et al. [33] in the context of colorectal cancer.
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Figure 2.1(b,c) suggests that in terms of tissue architecture, and in the presence of hierarchical lineages, there are multiple arrangements that are all, in principle, capable
of maintaining balanced tissue turnover. Each arrangement preserves the number of
cells in each compartment in the face of divisions triggered by cell deaths in the top
compartment. Because each cell division is associated with a probability of harmful
mutations, the question then becomes if there is a preferred strategy for a tissue to
arrange its turnover and/or compartment sizes in order to minimize the number of
mutants generated.
The goal of this work is to describe different differentiation/proliferation patterns
and their effect on cancer generation in a hierarchically organized tissue. First, we derive analytical expressions for the expected number of mutants in each compartment,
as a result of these chains of differentiation. This informs a deterministic approximation resulting in a set of differential equations describing mutant dynamics in
different compartments. It turns out that this methodology can be further adapted
to describe not only the approximately deterministic regime of large populations and
large mutation rates, but a more relevant regime of small populations and small mutation rates. We investigate the dynamics of our model in different scenarios, focusing
on different proliferation/differentiation probabilities and different compartment size
arrangements. In addition, we perform stochastic simulations to study the accumulation of mutations in a stochastic regime. We describe both one-hit and two-hit mutant
generation, and find the parameters that can be tuned to delay cancer initiation in
hierarchically organized tissues.

8

Chapter 2. Optimal homeostatic cell renewal

2.2

Methods: ordinary differential equations and
stochastic simulations

2.2.1

Trees and their probabilities

We start by formulating a metapopulation style model of stem cell lineages. Assume
that there are n + 1 compartments, C0 , . . . , Cn , with total constant cell numbers
N0 , . . . , Nn . Inside individual compartments, we assume complete mixing, and the
compartments are arranged linearly from the least mature, C0 , to the most mature,
Cn . At each time step, we remove an = 2n cells from compartment Cn . These cells
must be replaced by 2n divisions in different compartments. Because cells in compartment Cn do not proliferate, there will be an−1 = 2n−1 differentiation divisions
in compartment Cn−1 . Now, an−1 cells in this compartment must be replaced, either by differentiation divisions from compartment Cn−2 or by proliferation divisions
from compartment Cn−1 . Suppose there are an−2 differentiations and an−1 − 2an−2
proliferations. Next, an−2 cells from compartment Cn−2 must be replaced. This process gives rise to a division tree, which is uniquely characterized by the numbers of
differentiation divisions in each compartment:
{an−1 , . . . , a0 },

(2.1)

where an−1 = 2n−1 and
0 ≤ ai ≤ 2i , i = 0, . . . , n − 1.
The number of proliferations in compartment Ci is given by ai − 2ai−1 . The length
of the tree is the number of compartments that have nonzero numbers of differentiation events, and it varies from 1 to n. Proliferation and differentiation events are
assigned probabilistically, by means of the following process. Suppose ai cells must
be replaced in compartment Ci , that is, there are i openings to fill. Each cell is
replaced by a proliferation division in this compartment with probability vi . If the
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number of remaining openings is odd, then an additional proliferation division happens, such that the number of remaining openings is even, and they are then filled
by differentiation divisions from compartment Ci−1 . This allows us to calculate the
probability of a given tree defined by string (2.1). First we calculate the probability of
having ai differentiations in compartment Ci given that there are ai+1 differentiations
in compartment Ci+1 :
a

i+1
i
p(ai ) = Ca2ai+1
(1 − vi+1 )2ai vi+1

−2ai

a

i+1
i +1
(1 − vi+1 )2ai +1 vi+1
+ Ca2ai+1

−2ai −1

,

0 ≤ i ≤ n − 1,

where formally an = 2n and we use the following notation for the binomial coefficients:
Cnk =

n!
.
k!(n − k)!

We then have the probability of string (2.1):
P (an−1 , . . . , a0 ) =

n−1
Y

p(ai ).

i=0

In particular, since vn = 0, we obtain that an−1 = 2n−1 with certainty.

2.2.2

Chains of differentiation

The process previously described can be analyzed through division patterns or chains
of differentiation of a given length. What are the possible patterns of replacement of
2n cells? For example, if n = 3, we have 5 possibilities to replace 23 cells as illustrated
in figure 2.2. Figure 2.2(a) corresponds to 4 proliferation events in compartment C2
(4 differentiation chains of length one). Figures 2.2(b,c) represent one differentiation
chain of length 2 and two differentiation chains of length 1. Figure 2.2(d) corresponds
to 2 differentiation chains of length 2. In the last pattern, figure 2.2(e), we have one
differentiation chain of length 3.
Decreasing the probability of proliferation, v, increases the mean length of proliferation trees, and shifts the divisions toward the stem cell compartment, see figure
2.3.
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Figure 2.2: Possible patterns to replace 23 = 8 cells removed from compartment C3 .
The cells in red correspond to 8 cells discarded in C3 and the blue cells are dividing
cells (again, only dividing cells are shown, and the actual compartments contain more
cells). (a) All 4 cells that differentiated out to replace 8 cells in C3 are replaced by
4 proliferation events in C2 . This pattern occurs with probability v 4 . (b) and (c):
2 out of 4 cells that differentiated out from C2 are replaced by one differentiation
event from C1 (followed by a proliferation in C1 ) and two cells in C2 are replaced by
2 proliferation events in C2 . The probability of each of these patterns is v 2 (1 − v)2 .
(d) The 4 cells that differentiated out from C2 are replaced by 2 differentiations C1 ,
followed by 2 proliferation events in C2 . The probability of this pattern is (1 − v)4 v 2 .
(e) Similar to (d), except that the 2 cells in C1 are replaced by a differentiation from
C0 followed by a proliferation event. This pattern occurs with probability (1 − v)6 .

2.2.3

The expected number of mutants

Let us suppose that in each compartment, the number of mutants is given by mi ,
0 ≤ i ≤ n. We would like to calculate the expected change in the number of mu-
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Figure 2.3: Properties of division trees as a function of v, the probability of proliferation in compartments 1, . . . , n − 1. (a) Mean tree length, defined as the mean number
of compartments involved in the division trees. (b) P
Mean division position. For an
n
−n
individual tree, sequence (2.1), this is defined as 2
i=0 2i(ai − ai−1 ); plotted is the
expectation of this quantity across all the trees. In this example, n = 4.
tants after 2n cells are removed in compartment Cn . To do this, let us determine the
expected change in the number of mutants associated with a particular tree, string
(2.1). This can be done by considering the change resulting from ak differentiations
from compartment Ck to compartment Ck+1 and ak+1 − 2ak proliferations in compartment Ck+1 . These events will affect the numbers of mutants in compartments Ck
and Ck+1 .1
(a) When ak cells differentiate out of compartment Ck , 0 ≤ k ≤ n − 1, with probability
Pidiff = Cai k µik (1 − µk )ak −i ,
i of them may be mutants, where
µk =
1 Note

mk
,
Nk

that in the equations in this section we used combinatorial expressions obtained
from sampling with replacement. In the stochastic simulations below, sampling without
replacement was used, but it was established that sampling with replacement led to similar
results.
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which is the probability to pick a mutant among Nk cells. In this case, i mutants
are removed from compartment Ck and 2i mutants are added to compartment
Ck+1 . Further, among the remaining ak − i differentiations, there may be l
mutations which will increase the number of mutants in compartment Ck+1 by
l. To calculate the corresponding probability, we note that ak − i wild type
cells differentiating in compartment Ck will produce 2(ak − i) offspring, each of
which become mutants with probability u. Therefore, l mutants are generated
with probability
diff
l
Pi,l
= C2(a
ul (1 − u)2(ak −i)−l .
k −i)

The total change in compartment Ck+1 is then 2i + l, the total change in comdiff
partment Ck is −i, and this happens with probability Pidiff Pi,l
. These changes

must be summed up for 0 ≤ i ≤ ak and 0 ≤ l ≤ 2(ak − i).
(b) When ak+1 − 2ak cells proliferate in compartment Ck+1 , 0 ≤ k ≤ n − 1, with
probability
Pipro = Cai k+1 −2ak µik+1 (1 − µk+1 )ak+1 −2ak −i ,
i of them are mutants. This means that i new mutants are added to compartment Ck+1 . The remaining ak+1 − 2ak − i proliferating cells are wild type,
and it is possible that l of the offspring are new mutants. This happens with
probability
pro
l
Pi,l
= C2(a
ul (1 − u)2(ak+1 −2ak −i)−l .
k+1 −2ak −i)

The total change in compartment Ck+1 is then given by i + l and happens with
pro
. Again, these changes must be summed up for 0 ≤ i ≤ ak
probability Pipro Pi,l

and 0 ≤ l ≤ 2(ak − i).
(c) A special case is compartment C0 . Here, a0 cells will proliferate, and the number
of mutants is calculated similar to (b).
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(d) Another special case is compartment Cn . Cells do not proliferate in this compartment, but 2n cells are removed, and we need to calculate the expected
number of mutants removed, similar to Pidiff in (a).
For each tree, the expected change in the number of mutants can be expressed as a
vector whose components are obtained as the expected change in each compartment,
as calculated in (a-d) above. These vectors must be added together, weighted with the
probability of each tree. The resulting vector gives the time-derivatives of quantities
m0 , . . . , mn .
When ak cells differentiate out of compartment Ck , 0 ≤ ak ≤ n − 1, the expected
gain of mutants in compartment Ck+1 is given by
diff

αk+1

ak 2(a
k −i)
X
X
diff
=
(2i + l)Pidiff Pi,l
.
i=0

l=0

When ak+1 − 2ak cells proliferate in compartment Ck+1 , 0 ≤ k ≤ n − 1, the expected
gain of mutants in compartment Ck+1 is
pro

αk+1

ak 2(a
k −i)
X
X
pro
=
(i + l)Pipro Pi,l
.
i=0

l=0

The compartment Ck+1 loses mutants when ak+1 cells differentiate and migrate into
compartment Ck+2 , and the expected loss is
ak+1 2(ak+1 −i)
diff

βk+1 =

X

X

i=0

l=0

diff
(2i + l)Pidiff Pi,l
.

Thus the total change in the number of mutants in compartment Ck+1 is
pro
diff
diff
− βk+1
Tk+1 = αk+1
+ αk+1

The value Tk+1 represents the expected number of mutants in compartment Ck+1
produced by a single tree or chain of differentiation; because more than one tree
could affect the expected number of mutants in each compartment, we need to sum
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the contributions from all trees to compartment Ck+1 weighted by their probability.
This weighted sum defines the rate of change of the number of mutants in each
compartment:
X

ṁk =

Probtree Tktree ,

0 ≤ k ≤ n.

(2.2)

All trees

For the simplest cases, we list the ODEs derived by computing the expected number
of mutants produced by all possible chains of differentiation in each compartment.
We will use the assumption that vi = v for 1 ≤ i ≤ n − 1, which has been assumed
in other studies [5, 13, 19].

For the case n = 1 we have
ṁ1 = u + µ0 (1 − u) − µ1 ,
ṁ0 = 2u(1 − µ0 ).
For n = 2 we have
ṁ2 = 4(u + µ1 (1 − u) − µ2 ),
ṁ1 = 2(1 − v)2 (u + µ0 (1 − u) − µ1 ) + 4u(2 − v)v(1 − µ1 ),
ṁ0 = 2u(1 − v)2 (1 − µ0 ).
For n = 3 we have
ṁ3 = 8(u + µ2 (1 − u) − µ3 ),

(2.3)

ṁ2 = 4[u(1 − µ1 + v(2 − 3v + 4v 2 − 2v 3 )(1 + µ1 − 2µ2 ))
+(1 − v)2 (1 + 2v 2 )(µ1 − µ2 )],
ṁ1 = 2(1 − v)6 (u + µ0 (1 − u) − µ1 ) + 4u(2 − v)(1 − v)4 v(1 − µ1 )
+4uv(2 − 3v + v 3 )(1 − µ1 ),
ṁ0 = 2u(1 − v)6 (1 − µ0 ).

(2.4)
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The n + 1 linear ordinary differential equations derived here are applicable in the
high mutation rate/large population limit (uN  1). The unique fixed point of the
system, for all n, which is always stable, is
mi = Ni ,

0 ≤ i ≤ n.

In figure 2.4, we show the number of mutants in each of 4 compartments (assuming
n = 3) as a function of time, obtained from numerical solution of equations (2.3-2.4).
The number of mutants reaches saturation in each compartment; first in the top
compartment (C3 ), followed by compartment C2 and so on, as clearly seen for v = 0.9
(for v = 0.1 the differences are more subtle and cannot be seen in the logarithmic
scale of the figure). The dynamics for two different values of v are presented. The
larger the value of v, the longer it takes for the lower compartments to reach their
equilibrium values. This is because for large proliferation probabilities, long trees are
unlikely and divisions rarely happen in the less differentiated compartments. Further
details of the deterministic regime are presented in appendix A.

2.2.4

Stochastic simulations

The stochastic process is simulated by replacing cells as described in section 2.2.1.
We track the numbers of mutants, mi , in each of the compartments of constant sizes
(Ni , i = 0, 1, . . . , n). Let us denote by wi = Ni − mi the number of wild type cells in
each compartment.
The initial number of mutants is zero, and the simulation proceeds as a sequence
of discrete updates. Each update starts with 2n cells removed from compartment
Cn . A mutant is discarded with probability

mn
,
mn +wn

otherwise, the cell discarded is a

wild type cell. The next step is to replace the 2n cells removed in compartment Cn .
Because cells in compartment Cn can not proliferate, 2n−1 cells differentiate out from
compartment Cn−1 . In each division, a mutant is chosen with probability
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Figure 2.4: The dynamics of the expected number of mutants for a scenario of 4
compartments, comparing behavior for low and high proliferation probabilities. In
the top graph, v = 0.1, and in the bottom graph, v = 0.9. In this figure we used n = 3,
u = 10−3 , and the compartment sizes are N0 = 103 , N1 = 104 , N2 = 105 , N3 = 106 .
which increases the number of mutants in compartment Cn by two while the number
of mutants decreases by one in compartment Cn−1 . If a wild type cell is chosen for
differentiation in compartment Cn−1 , a de-novo mutant is produced with probability
u, such that the number of mutants increases by one in Cn . The number of wild-type
cells is decreased by one in Cn−1 . There are altogether 2n−1 differentiations from Cn−1
performed in this way.
Then, 2n−1 cells have to be replaced in compartment Cn−1 . Each of these cells
can be replaced by a proliferation event in Cn−1 with probability v. Cells that are
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not replaced by a proliferation event are replaced by a differentiation event from Cn−2
with probability 1−v. If the number of cells to be replaced by differentiation events is
odd, we add an extra proliferation event in compartment Cn−1 so that the number of
remaining openings is even. If the division event is a proliferation, a mutant is chosen
with probability

mn−1
mn−1 +wn−1

which increases the mutant population in compartment

Cn−1 by one. If the proliferating cell is a wild type cell, it produces a de-novo mutant
with probability u such that the number of mutants in compartment Cn−1 increases by
one. If the wild type cell did not mutate or a mutant was not chosen for reproduction,
the number of wild type cells in compartment Cn−1 increases by one. If the event is
a differentiation from compartment Cn−2 , mutants and wild type cells are updated in
the same way as described above for differentiations from compartment Cn−1 .
After this, there are a number of cells “missing” from compartment Cn−2 that
have to be replaced in a similar way. Every time a cell is chosen for division from
compartment Ci , it is a mutant with probability
mi
.
mi + w i

(2.5)

The process of cell replacement proceeds until compartment C0 is reached. Cells
“missing” from this compartment are replaced by proliferations in the same compartment with probability 1.
A comparison of the solutions of the ODEs and stochastic simulations is presented
in appendix B.

2.3

The role of proliferation rates and compartment sizes in mutant generation

The central question we address is what values of the proliferation probability, v,
produce fewer mutants; related to this, we investigate how the length of differen-
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tiation chains affects the growth of cancer cells. If low values of v produce fewer
mutants, this would imply that long chains of differentiation are favorable, as they
are likely to decrease the number of cancer cells; on the other hand, if high values of
v produce fewer mutants, short chains of differentiation would decrease the number
of cancer cells. In addition, we investigate how tissue architecture combined with the
proliferation probabilities affects mutant production.

2.3.1

De-novo mutant generation

In the ODE model derived here, mutations are generated constantly at a rate u. This
is a correct assumption with high mutation rates and high population numbers. In
smaller systems with low mutation rates, the processes of mutant (de novo) generation
and their clonal spread can be treated as separate. Mutant generation becomes a rare
event, and a single mutant that is generated gives rise to a clone that does not interfere
with the creation of other mutant clones. This regime can also be studied with the
help of the probabilities calculated above.
The removal of 2n mature cells from compartment Cn gives rise to a chain of
2n cell divisions that replenishes the lost cells. The probability of each such chain
is calculated above. Further, every chain gives rise to an expected change in the
mutant numbers in each of the compartments. This information can be used to study
the de-novo generation of mutants and their subsequent clonal spread. To calculate
the probability that a mutant will be generated in each of n + 1 compartments, we
evaluate the right hand side of system (2.2) with mi = 0 for all 0 ≤ i ≤ n (that
is, no prior mutations exist in the system). We obtain a vector proportional to
the mutation rate u. Normalizing this vector to create a probability distribution,
we obtain the probability to generate a mutant in each of the compartments. This
vector only depends on the quantities (v1 , . . . , vn−1 ), and not on the population sizes
of individual compartments.
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We can study the vector of probabilities of mutant generation by setting vi = v
for all 1 ≤ i ≤ n − 1 and examining the dependence on v. Smaller values of v give
rise to longer trees, and consequently higher probabilities of generating mutants in
the stem cell compartment. Larger values of v correspond to shorter trees, such that
mutants are not generated in the stem cell compartment. These trends are illustrated
in figure 2.5(a).

Figure 2.5: The role of the proliferation rate on mutant generation and mutant dynamics (the analytical approach). (a) The probability of generating a mutant in each
of the compartments for 6 different values of v: v = 0, v = 0.2, . . . , v = 1.0. (b) The
expected number of mutants produced from a single mutant cell in the absence of
further de-novo mutations, plotted as a function of time for three different values of
v. In this example, n = 4, u = 10−4 , and the compartment sizes are, from C0 to Cn ,
40, 80, 120, 160, 200.

2.3.2

Clonal dynamics of mutants

Once generated, a mutant undergoes clonal expansion and is also subject to being
flushed out of the system (depending on its location). Let us consider the clonal
propagation of mutants, in the absence of new mutations, which is achieved by setting
u = 0 in the main system of ODEs, equation (2.2). For simplicity, we first consider
the extreme scenario where vi = 0, that is, cells do not proliferate in any compartment
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except for C0 , and all trees have length n. In this case we obtain the following system:
ṁ0

=

ṁ1

=

ṁ2

=

ṁ3

=

0,


m0 m1
2
−
,
N0
N1


m1 m2
4
−
,
N1
N2


m2 m3
8
−
,
N2
N3

(2.6)
(2.7)
(2.8)
(2.9)

...
The structure of this system originates from the fact that in each compartment, k,
mutants can only enter by differentiation out of compartment Ck−1 , which is proportional to mk−1 /Nk−1 , and mutants leave by differentiation from compartment Ck ,
which is proportional to mk /Nk . In a more general case, we have
ṁk =

(v)
Kk



mk mk+1
−
Nk
Nk+1


,

(2.10)

(v)

for k > 0, where the constants Kk depend on the vector (v0 , . . . , vn ). To understand
why these type of dynamics occur for nonzero values of v, we note that if Q cells are
removed from compartment Ck this results in three effects:

• The expected number of mutants removed from Ck by differentiating out is
Qµk .
• On average, Qvk cells will be replaced by proliferations in compartment Ck ,
resulting in Qvk µk mutants added on average to Ck .
• The remainder of the cells, Q(1 − vk ), will be replaced by differentiations from
compartment Ck−1 . There will be Q(1 − vk )/2 such differentiations, resulting
in Q(1 − vk )µk−1 mutants added on average to compartment Ck .
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The net change in the mean number of mutants is then given by Q(1−vk )(−µk +µk−1 ),
which agrees with the above equations. The steady state of system (2.10) is given by
mk = m0

Nk
.
N0

(2.11)

The interpretation of this result is quite straightforward: the probability of fixation
of the mutant in compartment C0 is m0 /N0 , and the expected number of mutants in
all the downstream compartments is given by the corresponding compartment size
multipled by this fixation probability.
Depending on the origin of the mutation, the behavior of this system (and therefore, mutant clonal dynamics) will be different. Only in the case where the mutant is
introduced at C0 , is the steady state (2.11) nontrivial, that is, mutations will persist
in the system if the stem cell compartment acquires a mutation. If a mutant is introduced in any other compartment, there is transient dynamics, and then the mutation
will be flushed out, since m0 = 0 in (2.11).
The diagonal entries of the lower-triangular matrix in the linear system (2.10)
define the time-scale of the transient dynamics. The first diagonal entry is zero and
corresponds to the neutrality of the number of mutants in the stem cell compartment.2 The rest of the diagonal entries of the matrix in system (2.10) have quantities
Ni in the denominators (that is, larger compartments are characterized by slower
mutant dynamics), and the numerators are products of powers of 1 − vk . If all vk
are equal, then powers of (1 − v) define the decay of mutants. For small values of
the proliferation probabilities, the mutants are flushed out quickly because of a high
rate of differentiations leading to upward motion of cells through the compartments.
For larger values of v, mutants are flushed out slowly so they tend to accumulate in
compartments, giving rise to very long-lived mutant populated states. In the extreme
2 This

is a consequence of modeling the behavior of mutants deterministically. In a
stochastic system, the probability of increasing and decreasing the number of mutants in
C0 are equal to each other, leading to a symmetric Markov chain. The mean behavior
however is correctly captured by the present system.
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case of v = 1, only compartment Cn−1 divides, and mutants accumulate in that compartment (the right hand side of equation (2.10) is zero in this case, except for the
equation for mn ).

Figure 2.6: Comparison of mutant dynamics for different compartment size arrangements. The expected number of mutants is shown as a function of time for increasing
compartment size Ni = 80ei+1 (blue lines), constant compartment size (green lines),
and decreasing compartment size Ni = 80e5−i (yellow lines), for 0 ≤ i ≤ n = 4. The
total population size is the same for all systems. The rare mutation limit is assumed.
The probability of proliferation in each compartment is constant, vi = v for 0 < i < n,
and two values of v are used: v = 0.1 (solid lines) and v = 0.9 (dashed lines). (a)
Shorter time-scales. (b) Longer time-scales (note the log scale on the horizontal axis).

2.3.3

The role of proliferation in mutant generation and dynamics

As the value of v increases, there is a trade-off between two different trends associated
with the probability of proliferation: the shortening of the division trees on the one
hand, and a decrease in the mutant flush out rate. More precisely, small values of
v imply longer trees and a higher probability of generating mutants in the stem cell
compartment. When the mutants arise however, they will be flushed out quickly. On
the contrary, large values of v correspond to shorter trees, such that mutants are not
likely to be generated in the stem cell compartment. Once generated, however, the
mutants accumulate and persist for longer. The flushing out rate is proportional to
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(1 − v)b , where b is some large power, so realistically, non-small values of v result in
a very long-lived state populated with mutants.
These trends are illustrated in figure 2.5(b). We observe that for small values of
v, mutant accumulation is initially the least, but for large time, there is a significant
expected number of mutants in steady state (that is, a good chance that the mutants
fixate). For larger values of v, mutants tend to accumulate (as shown by the transient
increase in the number of mutants), but in the long run, the expected number of
mutants is smaller (a smaller chance that there is fixation in the system).

2.3.4

The role of compartment sizes

The question of optimal tissue architecture can be addressed in many different ways.
If the total number of cells and the number of compartments are fixed, there is a
very large number of ways to arrange individual compartment sizes. It is a difficult
problem to find the optimum among all possible compartment size arrangements. At
the same time, we know that the size distribution of compartments is determined by
more than one factor. For example, it would be unrealistic to say that the number of
cells in the SC compartment is large and the number of terminally differentiated cells
is small, because it is the more mature compartments that are there to perform the
function of the cells, and from the functional perspective, it is the numbers of such
cells that have to be maximized.
To study the question of mutant generation and the role of the compartment sizes,
we will not attempt to consider all possible compartment size arrangements. Instead,
we will look for general trends. From equation (2.10) we can see that to increase
the outflow of mutants from each compartment, one should decrease the Nk /Nk−1
ratio. Basically, the inflow and the outflow of mutants are both proportional to their
concentrations, and to increase the relative size of the outflow one should increase
the concentration in compartment Ck and decrease the concentration in compartment
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Ck−1 .
This simple argument provides an important constraint on mutant production and
dynamics. To study this constraint, we will consider three types of tissue architecture:
increasing compartment sizes, constant compartment sizes, and decreasing compartment sizes. The latter case is clearly unrealistic, and is included for completeness.
In the simplest case, we fix the probability of proliferation to be constant among
the compartments (for 0 < i < n), and compare the expected mutant production
following a (rare) mutation event for different arrangements of compartment sizes.
Figure 2.6 illustrates three different types of architecture: exponentially increasing
from N0 to Nn (blue lines), constant (green lines) and exponentially decreasing from
N0 to Nn (yellow lines). The two panels show the expected number of mutants on
different time-scales. In figure 2.6(a), on the time-scale of this plot, for small v,
decreasing compartment size minimizes mutations, and for large v, increasing size
minimizes mutations. In figure 2.6(b), the same plot is shown for longer time-scales.
Now decreasing compartment size minimizes mutations for both values of v. In appendix C we explore a model where the proliferation probability v is a function of
compartment sizes.

2.3.5

Stochastic simulations and a summary of trends

In this study, the number of mutants produced by a stem cell lineage system is
influenced by different factors. The two factors that we focused our investigation on
are the probability of proliferation in the compartments, v (such that low probability
of proliferation translates into having longer division trees), and the size of different
compartments. Here we summarize our findings and further illustrate them with
stochastic simulations, figure 2.7. In this figure, we present the mean dynamics of
mutations in different compartments, corresponding to two different values of v and
two different architectures, increasing and constant. As shown below, the behavior
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Figure 2.7: Mean number of mutants from 1000 stochastic simulations. We compare two
arrangements of the compartment sizes for n = 3: constant from C0 to C3 (N0 = 65, N1 =
65, N2 = 65, N3 = 65) and increasing from C0 to C3 (N0 = 20, N1 = 40, N2 = 80, N3 = 120).
(a) The mean number of mutants produced in compartments C1 , C2 and C3 for v = 0.9.
Note that no mutants were produced in compartment C0 over the time scale shown. (b)
The mean number of mutants produced in compartments C0 , C1 , C2 and C3 for v = 0.1. (c)
The mean of the total number of mutants comparing both architectures for v = 0.9 (blue
line) and v = 0.1 (green line). For all panels, solid lines correspond to constant architecture
and dashed lines to increasing architecture. In these simulations u = 0.001.

of the stochastic system is consistent with our predictions based on the ODEs, that
were described above.

1. In the short term, lower probabilities of cell proliferation (lower values of v)
tend to be advantageous, as they result in a lower overall number of mutants.
Transiently, for larger v one observes the effect of mutant accumulation, which
temporarily increases the number of mutants compared to low-v systems, see
figures 2.6 and 2.7(c). As v increases and the mean tree length decreases, there
is a trade-off between decreasing the probability of mutant creation in the SC
compartment and also decreasing the flush-out rate. In the long run, however,
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we observe that the latter tendency becomes less important, and larger values
of v result in a smaller overall number of mutants. This can be seen in figure
2.6, where the dashed lines corresponding to larger v are lower than the solid
lines (small v) for longer times. The same tendency is observed in stochastic
simulations of figure 2.7(c), where blue lines (v = 0.9) are below green lines
(v = 0.1) for large times. Note that the larger the value of v, the longer the
mutant accumulation stage persists, thus making values of v ≈ 1 unrealistic.
2. Larger values of v are again advantageous from the viewpoint of minimizing
the number of mutants in the stem cell compartment. With a shorter division
tree length, divisions in the stem cell compartment happen less often leading
to a lower number of mutations. This can be seen for example in figure 2.4
by comparing the black lines (the number of mutants in compartment C0 ); see
also figure 2.7, where for the time-scale of the simulations, no mutants have
appeared in C0 in (a) for v = 0.9, and there is a nonzero expected number of
mutants in C0 in (b) for v = 0.1 (depicted by black lines).
3. Given that the value of v is fixed, in the long run, architectures where all
compartment sizes are equal (marked “constant” in the figures) produce fewer
mutants than increasing architectures, see figure 2.6(b) and figure 2.7(c). Transiently, this trend can be reversed, see figure 2.6(a), for larger values of v.
Another scenario where increasing compartment sizes are advantageous arises
if we assume that the proliferation probabilities in compartments are correlated
with compartment sizes, such that differentiation from large to small compartments is favored. In this case, increasing architecture may give rise to fewer
mutants, see figure C.1(b,c).
4. Increasing architecture always minimizes the number of mutants in the stem
cell compartment. This follows from the ODE description, see for example, the
equation for the number of mutants in compartment C0 , equation (2.4). And
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the same trend is observed in the stochastic dynamics, see the black lines in
figure 2.7(b), where the dashed line corresponding to the increasing architecture
shows fewer mutants in C0 compared to the solid line for constant architecture
(please note that in this figure, in the long run, the number of mutants in each
compartment in the constant architecture is very similar, such that all the solid
lines are superimposed).

2.3.6

Generation of two-hit mutants

Stochastic simulations developed here were also used to investigate the dynamics of
two-hit mutant generation. In this setting, one-hit mutants were allowed to undergo
a secondary mutation process, and the simulations were stopped as soon as the first
two-hit mutant was generated. This situation corresponds to the scenario where
two-hit mutants are advantageous and do not obey the same homeostatic control
as the wild type cells or one-hit mutants. In this section, we used the two-sample
t-test to compare the obtained p-values. Figure 2.8 shows the histograms of times
when the first two-hit mutant was generated under different parameters. It presents
a comparison between different tissue architectures, panels (a) and (b), and different proliferation probabilities, panels (c) and (d). In particular we notice that the
largest difference in two-hit mutant generation times is experienced when we change
v (figure 2.8(c,d)). For both architecture types, low values of v lead to longer two-hit
mutant generation times. Therefore, we can say that from the viewpoint of two-hit
mutant generation, low values of v are advantageous. This can again be explained
by thinking about flush-out rates. Larger v lead to long-lived (although transient)
mutant accumulation in tissue compartments, which in turn results in a higher chance
of two-hit mutant generation. As a consequence, having lower proliferation rates and
longer differentiation trees results in slower two-hit mutant generation.
The differences in tissue architectures result in smaller differences in two-hit mu-
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tant generation time, but the trends we observe coincide with those seen in figure
2.6(a): for small values of v, increasing architecture leads to a faster production of
two-hit mutants (because it results in the fastest accumulation of one-hit mutants),
and for larger values of v, increasing architecture corresponds to the largest delay of
two-hit mutant generation, see also figure C.3.
Figure 2.9 further explores the differences between increasing and constant architecture by assuming that the proliferation probability is defined by the compartment
sizes according to formula (C.1) with β = 1. We observe that the constant architecture tends to delay the production of two-hit mutants compared to an increasing
architecture. This result follows from the fact that lower values of v slow down two-hit
mutant generation, as demonstrated above. Since the constant architecture results
in lower values of v, it results in the longest two-hit mutant generation times. Figure
C.3 shows an even stronger trend when the hypothetical, decreasing architecture was
investigated.
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Figure 2.8: Distribution of the generation times to second mutation, obtained from
5000 stochastic simulations. We consider two arrangements of the compartment sizes
for n = 3: constant from C0 to C3 (N0 = 65, N1 = 65, N2 = 65, N3 = 65) and
increasing from C0 to C3 (N0 = 20, N1 = 40, N2 = 80, N3 = 120). (a) The time to
observe a second mutant for both architectures and a high value of the proliferation
probability, v = 0.9. The mean time for constant and increasing architectures is 3.38
and 3.41 respectively; the p−value obtained in the t−test is p = 0.0023, indicating
that the means are different. (b) Same as (a) with a small value of the proliferation
probability, v = 0.1. The mean time for constant and increasing architectures is
3.68 and 3.61 respectively; the p−value obtained in the t−test is < 0.001, indicating
that the means are different. (c) and (d) The time to observe a second mutant for
a constant and increasing architecture, respectively, for small and high v. In these
simulations u = 0.001.
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(b)

(a)

Figure 2.9: Distribution of the generation times to second mutation, obtained from
stochastic simulations, in the case where v depends on the compartment sizes. We
perform 5000 stochastic simulations and compare two arrangements of the compartment sizes: (a) constant compartment size (red bars) and increasing (blue bars); (b)
decreasing (red bars) and increasing (blue bars). Compartment sizes are as in figure
Ni
, i = 1, 2.
2.8 and C.3. The proliferation probabilities are v1 = 1, v3 = 0, vi = Ni +N
i−1
We assume n = 3 and u = 0.001. In part (a), the mean time to a two-hit mutant
for constant and increasing architecture is 3.6387 and 3.5997 respectively; the p value
obtained by t-test is p < 0.001. In part (b), the mean time to a two-hit mutant for
decreasing architecture is 3.7232; the p value obtained by t-test is p < 0.001.
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2.4

Discussion

In this chapter we considered the dynamics of mutant accumulation in hierarchical
tissues under homeostatic turnover. What tissue architecture can be considered optimal from the viewpoint of minimizing mutations? We have focused our attention on
two aspects of tissue architecture: (1) probability of proliferations/differentiations of
cells in compartments; and (2) compartment size.
The first aspect is the probability of cells in each compartment to proliferate.
Proliferation division is one way of replenishing cells that have been removed (by
differentiation) from the compartment; the other way is to replace “missing” cells by
a differentiation division from an upstream compartment. Therefore, by changing the
probability of proliferation (as opposed to differentiation) we change the probability
that an upstream compartment will be engaged, thus changing the length of a typical
hierarchical division tree. We have found that increasing v (the probability of proliferation) results in two clear tends: (i) the trees get shorter and it becomes unlikely
to acquire a mutation in more primitive compartments, and (ii) mutations that are
generated are flushed out more slowly from the non-stem cell compartments, and
tend to accumulate (at least, transiently). This interesting trade-off results in different “optimal” solutions, depending on the objective of optimization. If the goal is to
minimize the total number of one-hit mutants residing long-term in all compartments,
relatively large values of v are desirable. If on the other hand we want to protect the
stem cell compartment, then low values of v are superior. Finally, from the point of
view of two-hit mutant generation, again lower values of v are advantageous.
The latter result is important in the context of tumor suppressor gene inactivation, which is a common event in carcinogenesis. In tumor suppressor genes, such
as the APC gene that is inactivated in a large fraction of colorectal cancers, or Rb
gene responsible for retinoblastoma, both copies must be inactivated for the resulting cell to acquire a phenotypic change that eventually may lead to cancer. Tumor
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suppressor gene inactivation is often considered an early event in cancer progression,
and therefore a delay in this event is of crucial importance for evolution. Our analysis
indicates that in order to delay tumor suppression gene inactivation in a hierarchical
tissue, mitotic activities must be concentrated near the stem cell. This finding coincides with in vivo measurements performed in [22, 34], where divisions were more
often observed near the bottom of the hierarchical compartment.
Other, indirect pieces of evidence pointing toward the protective potential of cell
division regulation come from studies that investigate the connection between loss of
differentiation and cancer. Our result that small values of the proliferation probability v lead to double-hit mutant suppression is consistent with the findings of [35],
who reported that overexpression of protein kinase CβII induced colonic hyperproliferation, and thus, increased the risk of colon carcinogenesis. This behavior has also
been observed in other types of cancers, where a disruption in differentiation patterns
might increase the risk of cancer [33, 36–39]. Tenen [40] explained that the loss of differentiation is an important component of many cancers, specifically, haematopoietic
transcription factors are crucial for differentiation to particular lineages, and their disruption is critical in acute myeloid leukemia (AML) development. Researchers have
also found that mutations related to brain cancer and leukemia cause the production
of an enzyme that can reconfigure on–off switches across the genome and stop cells
from differentiating [41–43].
We should also discuss this result in the context of the previous theoretical work by
[5] and [8]. In both of these papers, variants of a linear model of the colon were investigated, where individual cells were arranged in a linear array and where dividing cells
pushed out their neighbors upstream [44]. Interestingly, while both papers found that
divisions near the stem cell compartment (the “bottom-high” division distribution)
resulted in lowering the risk of secondary mutations experienced by existing one-hit
mutants, the overall two-hit mutant generation was found by [8] to be accelerated in
this case (and the “top-high” division distribution, where most divisions happen near
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the top, was shown to lead to a delay in two-hit mutant production). This pattern is
different from the result reported in the present model, and the difference stems from
the modeling assumptions: the linear model was adopted by [5, 8], whereas a model
with separate compartments that experience a certain degree of mixing was considered here (similar in spirit to metapopulation models that are often used in population
biology, see e.g. [45–48]). In the present model, the linear arrangement is not 1-cell
thick, but instead, there is a possibility that mutants can accumulate, or “get stuck”,
in a compartment that has a size greater than one cell. This is in contrast to the
linear model, where such a possibility does not exist, and each mutant will inevitably
be pushed toward death at the top of the crypt in a regular fashion. The tendency
of mutants to accumulate in the presence of a large proliferation probability discovered in the present setting, points toward a possibility that is ignored in the linear
models. In a sense, this is similar to the differences between one-dimensional spatial
population models on the one hand, and two-/three-dimensional population models
or metapopulation models on the other, see also [49, 50] for discussion of these issues.
Mutant spread is greatly restricted in one-dimensional geometry, whereas there are
different ways to spread in higher dimensions or in metapopulations.
The second aspect of architecture investigated here is the arrangement of compartment sizes. It is physiologically determined that the top compartment containing
the most mature cells performing their function in the organ, must be the largest.
Under this restriction, there is a great variety of ways in which sizes of consecutive
compartments can be arranged. In this paper we show that the size of the upstream
compartments matter when it comes to delaying mutant production in a hierarchical tissue. We found that the smaller the differences in the relative compartment
size, the longer it takes on average to generate a double-hit mutant. This suggests
the existence of evolutionary pressure to equalize compartment sizes to facilitate the
flushing out of mutant cells.
Next, we would like to interpret our model and its implications in the broader
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context of tissue architecture and the development of multicellular organisms. We
can view tissue as the “functional unit” consisting of the physiologically necessary,
fully mature cells, and a “support unit” consisting of less differentiated cells that do
not perform the same function but are there to support and replenish the cells from
the functional unit. The question then becomes, how to best organize the support
unit that maintains a certain number of “functional” cells, see also [11, 51]. As
one extreme scenario, one can envisage a great number of very short division trees
where more or less each mature cell is replenished by divisions of its own stem cell.
At the other extreme, it could happen that all the mature cells are replenished by
means of an enormously long division tree, and are all part of the same large lineage
stemming from a common SC. Our model is capable of distinguishing between these
two extreme possibilities (and the whole range of intermediate possibilities). If 2n cells
are removed, the longest division tree has length n and the shortest has length 1. If
v = 0, then the longest tree is always utilized. If v = 1, then only the shortest trees are
activated, and only cells in one upstream compartment (compartment Cn−1 ) divide.
If this was the evolutionarily preferable scenario, this would mean that compartment
Cn−1 is essentially the SC compartment, and that only one division step separates
SCs from fully differentiated cells. If an intermediate value of v was selected, then
the size of stem cell lineage would be defined by the length of a typical division tree
corresponding to this value of v, and the upstream compartments that hardly ever
divide would eventually be eliminated. Our results point towards the evolutionary
utility of lengthening of stem cell lineages, because decreasing v leads to an increase in
the two-hit mutant generation time. This process of lengthening of stem cell lineages
however has to be limited by other factors, such as geometric constraints and the
necessity of spatial distribution of lineages (for example colon crypts).
Incidentally, our result whereby lengthening of the SC lineages is preferred, is
again different from the previous one obtained in [51], for the same reason that was
highlighted above: the present model allows for mixing in the compartments, whereas
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the older model of [51] is rigid in the same way as the linear model of [5] (although it
is not a linear model but rather a sequence of deterministic divisions on a binary tree,
where randomness only comes about when creating de-novo mutations, see [20]).
The hierarchical model considered here, although less rigid in terms of division patterns compared with the linear model of [5] and the binary model of [51], is obviously
still a simplification of reality. There are many extensions that can be introduced into
this model. Somatic mutations are not necessarily neutral, they might be disadvantageous, or advantageous. In this context, a fitness advantage or disadvantage might be
assigned to mutants to study how it impacts the mutant population. Another important feature that could be added to our model is a replication capacity. This could be
done by assigning a maximum number of divisions to each compartment, which would
definitely have an impact on the type of chains of differentiation observed and therefore, on mutant development. It has been shown that a finite, and relatively small,
replication capacity (between 50 and 70 divisions [52]) is a mechanism of protection
against cancer in hierarchically organized tissues [32].
Finally, we note that the present model takes the metapopulation approach to
spatial relationships among cells. It can be refined by adopting a fully spatial, twoor three-dimensional description, for example, a cellular automaton or a hybrid model
with a degree of cell migration included. It will be interesting to see how the properties of this model change under such a refinement. The main finding of the present
model is that lowering the probability of proliferation in each compartment and compensating by differentiations in longer division trees leads to a delay in two-hit mutant
generation. We predict that this result should continue to hold in the fully spatial
case.
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3.1

Introduction

During homeostasis, cell replacement in some hierarchically organized tissues is neutral [28, 29]. When mutations arise, they likely confer a fitness advantage or disadvantage to the cells. It is well known that tissues evolve to minimize the risk of
accumulation of mutations to prevent cancer [2, 9, 53]. Multiple mechanisms of protection against cancer have been identified such as the hierarchical organization of
most tissues, the proliferation patterns for self-renewal, slow division rates, and the
type of cell division [1–8].
Most hierarchically organized tissues are composed of a small number of quiescent
and active stem cells, a relatively large pool of transit amplifying cells (TACs), and
mature differentiated cells. Cells in the mature differentiated part of the hierarchy
are constantly discarded and replenished to maintain homeostasis. This is a process
carried out by TACs and stem cells which replace those discarded cells via different
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patterns of cell proliferation and differentiation. The spatial organization of most
tissues works together with cell division patterns to delay the onset of cancer [5, 8, 13].
It has been shown that proliferation patterns with division activity near the stem cell
compartment are optimal to eliminate single mutants in colonic crypts [5], whereas
Shahriyari and colleagues [8] recently showed that proliferation patterns with activity
in more mature compartments are optimal to delay the accumulation of double-hit
mutants in the colon and the intestinal crypts. How spatial organization, division
patterns and selection interact to delay the accumulation of mutations is a question
that is far from being fully understood.
Tissues can be suppressors or amplifiers of selection. A suppressor of selection
reduces the probability of fixation of advantageous mutations and increases the probability of fixation of disadvantageous mutations [54]; while an amplifier acts in the
reverse direction. Hindersin and colleagues [55] showed that in systems that are
composed of few cells, amplification or suppression of selection are a result of subtle
changes in the tissue architecture. In this context, graph theory has been an important tool to investigate tissue architecture and natural selection [54]. For example,
the linear process or directed line where the first cell is the root and every cell can only
replace its immediate successor has been shown to be a suppressor of selection [9].
This linear process has been applied to the colon crypts [5], although other directed
and undirected graphs have also been investigated in the colonic crypts [55]. Ideally,
if most of the mutations are advantageous, the tissue should act as a suppressor of
selection to minimize the risk of cancer. On the other hand, if most of the mutations
are deleterious, tissues should evolve and act as amplifiers of selection to minimize the
accumulation of such mutations, and therefore, the loss of functionality. Whether a
tissue should be a suppressor or amplifier of selection is a complex question that does
not have a simple answer. It depends on tissue architecture, and we hypothesize that
it also depends on the division patterns observed while the tissue is renewing. We
consider an optimal strategy as one where the accumulation of one-hit or second-hit
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mutants is minimized.
In chapter 2 we propose a model for tissue renewal where a fixed number of cells
is discarded in the compartment of mature differentiated cells. This triggers chains
of differentiations which can be short, implying that most of the activity is in the
more differentiated cells, intermediate, or long, implying that the stem cell compartment participates in cell division more often. In this chapter, we examine whether
this model is a suppressor or amplifier of selection. Specifically, we investigate how
changes in the organization of compartment size impact the growth of advantageous
and disadvantageous mutations. In addition, we study how advantageous and disadvantageous mutations grow under different patterns of proliferation/differentiation.
This allows us to study tissue renewal under different proliferation patterns, different
tissue architectures and different fitness values, which are key to understanding when
tissue renewal becomes an amplifier or suppressor of selection. Thus we investigate
biologically relevant scenarios that could put the tissue at risk of failure, which would
indicate that the tissue does not evolve accordingly to maintain functionality.
We start by investigating the accumulation of one-hit mutants with a given fitness
advantage or disadvantage in large and small systems using an ODE approximation
and stochastic simulations. We also explore the time to observe a second-hit mutant.
In these investigations, we study the role of tissue architecture and proliferation patterns for different values of the fitness parameter. We find that the hierarchically
organized tissue is a strong suppressor of selection. In the context of second-hit mutant production, an architecture with a small number of SCs and larger number of
TACs, and long chains of differentiation could be optimal to minimize the risk of
cancer by means of minimizing the time for a second mutation to occur.
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3.2

Methods

We propose a compartmental model to study the role of mutant fitness during homeostatic cell renewal in hierarchically organized tissues. We use the results obtained in
chapter 2, where we derived an approximation of the expected number of mutants in
compartment Ci , i = 0, . . . , n, given that 2n cells are discarded in compartment Cn .
This approximation was derived by adding the expected number of mutants produced
by each chain of differentiation to every compartment. The difference with respect
to the previous model is that the probability of choosing a mutant for reproduction
is proportional to both the frequency of mutants in the population and the fitness of
mutants, r. We assume that neutral mutations have fitness r = 1, disadvantageous
mutations have fitness r < 1 and advantageous mutations have fitness r > 1. We
propose a model where mutants have the same fitness during their entire life span
and only one type of mutation can occur. Although this represents a simplification,
the approach allows us to study how a specific type of mutation accumulates in a hierarchically organized tissue undergoing cell renewal. For example, for a tissue with 4
compartments, the dynamics of the expected number of mutants, mi , in compartment
i are given by
ṁ3 = 8(u + µ2 (1 − u) − µ3 ),

(3.1)

ṁ2 = 4[u(1 − µ1 + v(2 − 3v + 4v 2 − 2v 3 )(1 + µ1 − 2µ2 ))

(3.2)

+(1 − v)2 (1 + 2v 2 )(µ1 − µ2 )],
ṁ1 = 2(1 − v)6 (u + µ0 (1 − u) − µ1 ) + 4u(2 − v)(1 − v)4 v(1 − µ1 )

(3.3)

+4uv(2 − 3v + v 3 )(1 − µ1 ),
ṁ0 = 2u(1 − v)6 (1 − µ0 ).

(3.4)

where the probability of choosing a mutant for reproduction is defined as
µi =

rmi
, i = 0, . . . , n
rmi + wi
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where wi = Ni −mi is the number of wild type cells in compartment Ci . Ni represents
the size of compartment i, i = 0, . . . , n, v is the proliferation probability, and u is the
mutation rate. For this approximation, we use sampling with replacement, a method
identical to that utilized when neutral mutations were investigated. Similar to our
study in chapter 2, we will apply this approximation to systems with large population
sizes where mutants grow in a deterministic fashion, such as the haematopoietic
system, and, under certain assumptions, we also apply it to small systems where
mutations are rare events.
To investigate the dynamics of disadvantageous and advantageous mutations for
systems with small population sizes such as the small intestine, stochastic simulations
are also performed. We perform stochastic simulations in scenarios where mutants
have an advantage or disadvantage for different values of the proliferation probability.
In addition, different arrangements of the population sizes are studied. The stochastic
simulations are fully described in chapter 2, section 2.2.4, where the model for optimal
tissue renewal in hierarchical tissues was introduced. In the stochastic simulations,
sampling without replacement is used, so that the probability to select a mutant with
fitness r in compartment i during a division event is given by
µi =

rmi
, i = 0, . . . , n,
rmi + wi

where wi is the number of wild type cells in compartment i. In this case, wi + mi is
different to Ni , which is observed when sampling is done without replacement.

3.3
3.3.1

Results
The ODE approximation

Using the ODEs (3.1-3.4), the model is investigated in a scenario where mutants with
a fitness advantage or disadvantage are constantly produced, which requires systems
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with large population sizes and (or) high mutation rates. We investigate the dynamics
of the ODE approximation for advantageous and disadvantageous mutations in a large
system. In figure 3.1 we plot the total number of mutants as a function of the fitness
parameter r obtained by solving the ODE approximation for increasing and constant
architectures. Initially, for an increasing architecture, the number of advantageous
mutations will be larger than the number of disadvantageous mutations (figure 3.1,
top panels). However, as time increases, the number of advantageous mutations
becomes smaller than the number of disadvantageous mutations. Eventually, all types
of mutations will reach similar numbers (figure 3.1, bottom panels). This indicates
that the tissue is a strong suppressor of selection because it reduces the probability
of fixation of advantageous mutants. This is confirmed by examining the steady state
of the ODEs, mi = Ni , i = 0, . . . , n, which is independent of the fitness value, r.
Interestingly, we observe that when the population sizes in all 4 compartments are
equal (Ni = 277750, i = 0, . . . , 3), even for small times, the total number of mutants
decays as the fitness parameter r increases. As time increases, the qualitative behavior
of the scenario with constant architecture is identical to the scenario with increasing
architecture (figure 3.1).
Although the number of mutants reaches a steady state value that is independent
of fitness, we observe that the transient dynamics are greatly influenced by other key
components of the model: specifically the proliferation probability, v, and the tissue
architecture. As we found for neutral mutations, the value of v that minimizes the
number of advantageous or disadvantageous mutations is time dependent. As time
increases, the optimal v is shifting towards an intermediate or high value of v. We
observe that in the long run, small values of v produce the largest number of mutants,
which is similar to the result we obtained for neutral mutations (figure 3.2). Regarding the tissue architecture, we observe that the transient dynamics of all mutants is
characterized by a greater accumulation of mutations when the compartment sizes
increase from the stem cell compartment to the mature compartment. These dynam-
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ics are the same as we observed for neutral mutations. In section 3.3.2 we present
further details about the role of tissue architecture.

3.3.2

Fitness in a stochastic regime

In this section we investigate small systems where mutations with a given fitness are
rare events. If we assume that once a mutant is generated, no more mutations occur,
u = 0, we obtain a similar system of ODEs to the one obtained for neutral mutations.
If we further assume that vi = 0, i = 1, . . . , n − 1, we arrive at

ṁ0 = 0,


rm1
rm0
−
,
ṁ1 = 2
rm0 + N0 − m0 rm1 + N1 − m1


rm1
rm2
ṁ2 = 4
−
,
rm1 + N1 − m1 rm2 + N2 − m2


rm3
rm2
−
,
ṁ3 = 8
rm2 + N2 − m2 rm3 + N3 − m3
..
.

The steady states are identical to those found for neutral mutations:
mk = m0

Nk
.
N0

(3.6)

Thus, the steady state does not depend on r as was found for large systems (section
3.3.1), where the number of mutants reached a steady-state value independent of the
fitness parameter. This confirms the role of the tissue as a suppressor of selection,
because the probability of fixation is independent of the fitness parameter, r. In general, if the proliferation probabilities vi are non-zero, the steady state is unchanged,
although the values of vi delay or accelerate the growth rate of mutants. High values
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Figure 3.1: The total number of mutants as a function of the fitness parameter r, obtained from the ODE approximation for different values of the proliferation probability v and two architectures. We consider a scenario of 4 compartments with populations increasing from compartment C0 to compartment Cn
(N0 = 103 , N1 = 104 , N2 = 105 , N3 = 106 ) and a tissue architecture with constant
compartment sizes (Ni = 277750, i = 0, . . . , 3). Each panel represents different time
values. The mutation rate is u = 10−3 and n = 3.
of v delay the rate at which mutants are flushed out, but eventually fewer mutants
are produced; on the other hand, small values accelerate the rate at which mutants
are flushed out, although the probability of fixation in all compartments increases.
The role of v is independent of the fitness of the mutants, even though the transient
dynamics of mutations with a given fitness advantage or disadvantage are time dependent. Stochastic simulations also reflect the same behavior: eventually high values of
v will accumulate fewer mutants than small values of v (figure 3.3).
From the stochastic simulations we also find that disadvantageous mutations accumulate slightly more than advantageous mutations. Although, as time increases,
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Figure 3.2: The total number of mutants as a function of the proliferation probability
v, obtained from the ODE approximation for different values of the fitness parameter
r and two architectures. We consider a scenario of 4 compartments with populations
increasing from compartment C0 to compartment Cn (N0 = 103 , N1 = 104 , N2 =
105 , N3 = 106 ), and a tissue architecture with constant compartment sizes (Ni =
277750, i = 0, . . . , 3). Each panel represents different time values. The mutation rate
is u = 10−3 and n = 3.
all types of mutation reach similar numbers, as was found in the ODE approximation
for the deterministic regime. As we observed in previous chapter, arrangements of the
populations where compartment sizes decrease from the stem cell compartment to the
top mature differentiated compartments are preferred to delay the accumulation of
one-hit mutants (see figure 3.1). These observations are confirmed by the stochastic
simulations, where for the two values of r investigated (r = 0.7 and r = 1.3), these
patterns hold (figure 3.4).
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Figure 3.3: Comparing small and high values of v for increasing and constant architectures, and advantageous and disadvantageous mutants from 1000 stochastic
simulations. (a) Small (solid lines) versus high (dashed lines) values of v for increasing architecture (N0 = 20, N1 = 40, N2 = 80, N3 = 120) and two values of the fitness
parameter r. (b) Small (solid lines) versus high (dashed lines) values of v for constant architecture (N0 = 65, N1 = 65, N2 = 65, N3 = 65) and two values of the fitness
parameter r. The mutation rate is u = 10−3 and n = 3.

3.3.3

Fitness and second-hit mutants

We now allow for the possibility of a second mutation to occur. We study this scenario via stochastic simulations; we track the time when a second mutation occurs
and immediately stop the simulation. We start by comparing different values of r
for a given architecture and proliferation probability v. In this section, we used the
two-sample t-test to compare the obtained p-values. Interestingly, we find that with
increasing architecture (figure 3.5(a,b)), there is no significant difference in the mean
time to observe a second mutation when comparing advantageous and disadvantageous mutations for both high v (p = 0.4314) and small v (p = 0.8231). On the other
hand, for constant architecture (figure 3.5(c,d)), advantageous mutations produced
second-hit mutants faster than disadvantageous mutants for high v (p = 1.27 × 10−4 ).
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Figure 3.4: Comparing increasing and constant architectures for advantageous and
disadvantageous one-hit mutants. The mean of the total number of mutants from
1000 stochastic simulations. (a) Increasing (solid lines) versus constant architecture
(dashed lines) for a small value of v and two values of the fitness parameter r. (b)
Increasing (solid lines) versus constant architecture (dashed lines) for a high value of
v and two values of the fitness parameter r. In both panels, black lines correspond to
deleterious mutations (r = 0.7) and red lines correspond to advantageous mutations
(r = 1.3). For constant architecture, the compartment sizes are N0 = 65, N1 =
65, N2 = 65, N3 = 65, and for increasing architecture, the compartment sizes are
N0 = 20, N1 = 40, N2 = 80, N3 = 120. The mutation rate is u = 10−3 and n = 3.
For small v (p = 0.0854) there is no significant difference in the mean time. Significant differences in the mean time to observe a second-hit mutant were also observed
when we investigated a decreasing architecture. For small v, advantageous mutants
produced a second-hit mutant faster than deleterious mutants (p < 0.0001, figure
3.6(b)), and for high v, disadvantageous mutants produced second-hit mutants faster
than advantageous mutants (p = 0.0213, figure 3.6(a)).
The results described above provide important insights into the role of tissue architecture in minimizing cancer risk. When a second mutation occurs, the increasing
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Figure 3.5: Comparing advantageous and disadvantageous mutants. Distribution
of the time to observe a second mutation, obtained from 5000 stochastic simulations. (a) and (b) Comparing advantageous and disadvantageous mutations for
increasing architecture and high and small v, respectively. (b) and (d) Comparing advantageous and disadvantageous mutations for constant architecture and high
and small v, respectively. For constant architecture, the compartment sizes are
N0 = 65, N1 = 65, N2 = 65, N3 = 65, and for increasing architecture, the compartment sizes are N0 = 20, N1 = 40, N2 = 80, N3 = 120. The mutation rate is
u = 10−3 and n = 3.
architecture with a small number of stem cells, which is the typical organization of
tissues such as the colon and the small intestine, manages to keep the distribution
of time to observe a second-hit mutant the same for both advantageous and deleterious mutations. This indicates the robustness of the increasing architecture and its
role in minimizing the risk of cancer. On the other hand, when this architecture is
altered, so that the stem cell compartments have larger population sizes, then advantageous mutants could increase the time to observe a second mutation compared to
disadvantageous mutants, or vice versa depending on the proliferation value and the
compartment architecture. Under these circumstances, there would be an increased
chance of fixation of advantageous or deleterious mutations, which might put the
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Figure 3.6: Comparing advantageous and disadvantageous mutants for decreasing architecture. Distribution of the time to observe a second mutation from 5000 stochastic
simulations. (a) and (b) Comparing advantageous and disadvantageous mutations for
decreasing architecture and high and small v, respectively. The compartment sizes
are N0 = 120, N1 = 80, N2 = 40, N3 = 20. The mutation rate is u = 10−3 and n = 3.
tissue at risk. Therefore, an increasing architecture seems to be a good evolutionary
strategy, which combined with “the best” proliferation pattern, can minimize the risk
of cancer.
Similar to what we found for neutral mutations, small values of v delay the time
to observe a second-hit mutant compared to high values (figure 3.7, for all panels,
p < 0.05). Importantly, this result holds for all architectures considered, and both advantageous and disadvantageous mutations. Therefore, an optimal strategy to delay
the time to observe a second-hit mutant, which would be equivalent to minimizing
the risk of cancer, corresponds to long chains of differentiation where the division
activity is near the stem cell compartment.
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Figure 3.7: Comparing small and high values of v, for increasing and constant architectures when mutants are advantageous or disadvantageous. Distribution of the
time to observe a second mutation from 5000 stochastic simulations. (a) and (b)
Comparing small and high values of v for advantageous mutations and increasing and
constant architectures, respectively. (c) and (d) Comparing small and high values of
v for disadvantageous mutations and increasing and constant architectures, respectively. For all panels, the mean time to two-hit mutants is larger for small v and the
p-values of the t-test performed on the log-transformed data are less than 0.05. For
constant architecture the compartment sizes are N0 = 65, N1 = 65, N2 = 65, N3 = 65
and for increasing architecture, N0 = 20, N1 = 40, N2 = 80, N3 = 120. The mutation
rate is u = 10−3 and n = 3.

3.4

Discussion

We propose a model to study homeostatic cell renewal under a selective pressure. The
model incorporates key variables for cell renewal such as tissue architecture, proliferation patterns and a fitness value. This allows us to study different optimal strategies
that delay the accumulation of one- and two-hit mutants when mutations gain a fitness advantage or disadvantage during cell division. During cell renewal, tissues can
be suppressors or amplifiers of selection. We find that whether the tissue becomes an
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amplifier or suppressor of selection is strictly related to the tissue architecture and
the proliferation patterns considered.
First, we discuss the results in terms of accumulation of one-hit mutants. We
find that the steady state of the system is independent of the fitness parameter and
is identical to the steady state found for neutral mutations, which depends on the
probability of fixating the stem cell compartment so that mutations arising in a
compartment different to the stem cell compartment are flushed out of the hierarchy.
This demonstrates that the tissue is the strongest suppressor of selection in the sense
that it reduces the probability of fixation of mutants in the stem cell compartment
to a value

1
,
N0

where N0 is the size of the stem cell compartment. Our model is

somewhat similar to the linear model proposed by [5], which is a structure that was
found to suppress selection [9, 54]. Our model differs from the linear model in the
sense that it can be thought of as a metapopulation-style model. In the linear model,
cells are arranged in a 1-cell thick chain, in which mutants are pushed toward the
top of the hierarchy where they are discarded. In our model, mutants still “travel”
from the stem cell compartment to the top compartment, but on the way they can
accumulate in all compartments, which is not captured by a one-dimensional array.
The transient dynamics are characterized by greater accumulation of advantageous
mutants for early times, and as time increases, deleterious mutants reach similar (or
higher) numbers. We interpret this result in terms of cell aging and cancer risk. It
is well known that cancer incidence increases with age. As cells age, they lose fitness
and are more likely to get damaged, which translates into loss of functionality of the
tissue and a higher risk of mutations [56–59]. This indicates that the ability of the
tissue to maintain fitness is crucial to minimize cancer risk [59]. Many long-lived
multicellular organisms such as large animals like whales and elephants, have evolved
highly fit stem cell populations, which leads to lower cancer incidence, despite having
larger stem cell pools which makes them a larger target for mutations [59].
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When we study second-hit mutants, we observe that tissue architecture plays a key
role in delaying the time to observe a second-hit mutant. First, we found that with
an increasing architecture, deleterious and advantageous mutations produced two-hit
mutants almost at the same times, which indicates that an increasing architecture
is a robust evolutionary strategy in terms of minimizing cancer risk. This could be
explained by the fact that in an increasing architecture, the stem cell compartment
has a small number of cells, which makes it a smaller target for oncogenic mutations.
Also, when mutations arise, they are more likely to be pushed toward the top of the
hierarchy where they have a higher chance to be eliminated. On the other hand,
when we considered a constant architecture (with a larger stem cell pool compared
to an increasing architecture), we observed that advantageous mutants could produce
a second-hit mutant faster than deleterious mutants when the value of v was high,
indicating an amplification of selection, which could be a dangerous situation for
the tissue. When a decreasing architecture was considered, advantageous mutants
produced mutants faster than disadvantageous mutants for small values of v, and the
opposite occurred for high values of v, when disadvantageous mutants produced a
second-hit mutant faster. Thus, an increase in the stem cell pool could compromise
the functionality of the tissue by making it a larger target for oncogenic mutations.
This is emphasized for constant and decreasing architectures, where short chains of
differentiation could lead to hyper-proliferation, which is associated with an increased
risk of cancer [33, 35–39]. In addition, for all tissue architectures investigated, small
values of v (corresponding to long chains of differentiation) delayed the time to observe
a second-hit mutant compared to high values of v (short chains of differentiation).
This suggests that proliferation patterns where the division activity is concentrated
near the stem cell compartment are optimal to minimize cancer risk. This is explained
by the fact that small values of v increase the rate at which mutants are flushed out,
which reduces the accumulation of mutants.
In the model presented here, mutations are assumed to have a single identical
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fitness value for all time. An interesting addition to our model would be to investigate
the effects of a fitness parameter that changes as a function of time. This would
be a more realistic assumption given that as cells age, their fitness is reduced [59].
We hypothesize that our model would predict an increase in mutant accumulation
as fitness decreases with time, as observed in the current model when deleterious
mutations were investigated. Again, this would be associated with a higher risk of
cell damage, which can make oncogenic mutations more likely to occur. Another
feature that could be added is the possibility of having deleterious and advantageous
mutants simultaneously, which is not currently allowed in our model. This could be
done by assigning a different fitness value to cells, depending on the position in the
hierarchy. Stem cells could have the largest fitness value, and the higher the position
in the hierarchy is, the less fit cells would be.
Overall, we find that hierarchically organized tissues are suppressors of selection,
whereby an increasing architecture (small number of stem cells) and small values of
v (long differentiation trees) are robust evolutionary strategies to minimize the time
to observe a second-hit mutant. This can be associated with a reduction in the risk
of cancer, given that two mutations are enough to initiate a tumor for certain cancer
types such as colon cancer.
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4.1

Introduction

In the last decade, the immune system has been proven to play a crucial role in the
fight against cancer. Cancer immunotherapy, consisting of treatments that stimulate
the body’s own immune defenses, has become an important alternative and complement to traditional treatments such as chemotherapy. Immunotherapy includes
several different types of treatments such as monoclonal antibodies, cancer vaccines
and immune checkpoint inhibitors. Despite the success of immunotherapy, the design
of these treatments remains challenging, and several situations can lead to failure.
Understanding the interactions between the immune system and tumor cells is crucial when designing these types of treatments. In this regard, mathematical modeling
is a powerful tool that can help to disentangle this complex process and to design
better cancer treatment strategies.
An immune response against cancer is a complex process which requires the co-
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operation of different cell types and involves a variety of molecular mechanisms. The
immune system deploys an innate immune response that provides an early defense
against pathogens but it is the adaptive immune response that is capable of resolving
diseases [60]. Cytotoxic T lymphocytes, killer T cells that are part of the adaptive
immune system, are able to fight cancer once they are activated. The activation and
down regulation of T cells to trigger an immunologic response against cancer cells
is orchestrated by several costimulatory and inhibitory signals together with antigen presentation to T cells, which is carried out by antigen presenting cells (APCs)
[61–66].
In figure 4.1, we illustrate this process: tumor cells display antigen, and APCs,
such as dendritic cells, intake antigen and present it to the T cells in the context of
a major histocompatibility complex (MHC) molecule. Then, a costimulatory signal
is activated when the ligand B7 in the APC binds the receptor CD-28 in the T cell
[61]. Early after activation of T cells, immune checkpoints or negative signals are
activated, which downregulate the immunologic response. The most studied immune
checkpoints in clinical trials are cytotoxic T lymphocyte antigen 4, CTLA-4 [67–73]
and the programmed cell death protein, PD-1 [74–78]. There are other immunologic
checkpoints that have been tested and likely many that remain unknown [79–81].
Expression of the CTLA-4 antigen is initiated upon T cell activation, and it traffics to and accumulates in the immunological synapse, eventually attenuating or preventing CD28 costimulation by competition for B7 binding and negative signaling
[82–87]. PD-1 is also an inhibitory program of T-cell activity at a variety of stages of
the immune response when it interacts with its two ligands PD-L1 and PD-L2 [88–
90]. PD-L2 is predominantly expressed in APCs, whereas PD-L1 can be expressed
in many cell types, including cells of the immune system, epithelial cells, endothelial
cells, and tumor cells. PD-1 does not outcompete CD28 for binding to B7, as CTLA-4
does, but it inhibits T cell responses by interfering with T cell receptor signaling. An
extensive review of the immune checkpoints CTLA-4 and PD-1 can be found in [91].
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From a modeling perspective, the immune response can be thought of as a balance between positive and negative signals: positive signals upregulate production of
T cells after they encounter APCs, whereas negative signals are initiated after the
activation of T cells to downregulate T cells and maintain immunological homeostasis. In previous theoretical studies, little attention has been paid to understanding
the interactions between positive and negative signals: it is assumed that tumor cells
can impair the immune response, but additional pathways that can lead to its downregulation are ignored. Most of the attention has been focused on understanding the
role of antigen presentation by APCs and investigating how dendritic cell vaccination (DCV) can help to stimulate antigen reception by T cells during immunotherapy
[92–95]. Wodarz and Jansen [92] found that an immunologic response will be activated and sustained if the rate of antigen presentation/reception is relatively high.
The stimulation of antigen presentation by APCs to T cell receptors might be done
through a vaccine [96, 97], but if the immune checkpoints are activated, this could
potentially result in the increase of an inhibitory signal, as suggested by [98].
Our goal is to describe, with a simple mathematical model, the effects of antigen
presentation of APCs to T cells and the interaction of costimulatory and negative
signals (immunologic checkpoints). We also investigate the role of the initial number
of tumor and immune cells, because, for example, the absolute count of T lymphocytes is regarded as a positive bio marker during immunotherapy. Specifically, we
address three broad questions: Under what conditions can an immune response be
sustained in the presence of costimulatory and inhibitory signals? Is stimulation of
antigen reception signaling beneficial in the presence of inhibitory signals that activate proportionally to the encounter of loaded dendritic cells and T cells? How do
initial populations of immune cells and tumor cells affect an immune response in the
presence of costimulatory and inhibitory signals?
In this chapter, we first study the system at equilibrium and characterize 3 different types of equilibria. We then investigate how cancer and immune cell dynamics
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Tumor
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Figure 4.1: T cell activation and immune checkpoints. In order to activate, a T cell
requires antigen presentation by antigen presenting cells (APCs) through a major
histocompatibility complex (MHC) molecule and a costimulatory signal mediated by
B7 molecules in the APCs and the receptor CD-28 in the T cell. Early after activation, several inhibitory pathways are initiated, which downregulate T cell function
to maintain immunological homeostasis. The diagram illustrates how the immune
checkpoint, CTLA-4, is activated and one of the possible pathways of the immune
checkpoint, programmed cell death PD-1. This figure is a combination of figure 1 in
[65] and figure 1 in [98].
are affected by the rate of antigen reception and by the presence of costimulatory
and inhibitory signals. In addition, we examine how the initial tumor size, the initial
number of dendritic cells and the initial count of T cells impact the tumor cell dynamics during an immunologic response in the presence of costimulatory and inhibitory
signals. Finally, we perform a sensitivity analysis to investigate the effects of key
parameters on our results.
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4.2

4.2.1

Methods

The Model

We construct a system of ordinary differential equations that describes the interactions between a growing tumor cell population and a tumor-specific response by
cytotoxic T lymphocytes (CTL) under the action of positive signals and inhibitory
signals known as immunologic checkpoints. Our model is similar to that proposed by
Wodarz and Jansen [92], and it captures the basic interactions between the immune
system and tumor cells represented in other models such as [93]. In [92], it is assumed
that tumor cells impair the immune response through an inhibitory signal that occurs
after a T cell encounters a tumor cell, but this is only one of the possible ways in
which the PD-1 inhibitor might be activated. In our model we also include the effect
of an inhibitory signal that might occur after a positive signal is activated when a T
cell encounters a loaded APC. This is how the CTLA-4 immunologic checkpoint is
activated, and also one of the possible ways in which the immune checkpoint PD-1
protein is activated. We also model the effect of inhibitory signals differently from
[92]. In [92], the inhibitory signal activates proportional to the encounter of T cells
(T) and cancer cells (C) and directly reduces the population of activated T cells at
the rate qT C, where q represents the rate at which cancer cells remove T cells. In
our model, increasing the inhibitory signal reduces the activation rate of T cells instead of directly reducing the number of activated T cells. This accounts for different
effects of inhibitory pathways, such as impairing T cells from recognizing tumor cells
or undergoing cell division.
The model consists of 4 variables: tumor cells directly displaying antigen, C;
antigen-presenting cells (APCs), A; loaded APCs, D; and activated T lymphocytes,
T, which are able to kill cancer cells. The dynamics of these populations over time is
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described by the following system of differential equations:



C
− γT C
Ċ = rC 1 −
k
Ȧ = λ − αAC − δ1 A
(4.1)
Ḋ = αAC − δ2 D
Ṫ =

psT D
− uT.
b1 βT C + b2 sT D + n

The parameter r represents the maximum per capita growth rate of tumor cells; k
is the carrying capacity (in the absence of killer T cells); and γ is the killing rate when
a killer T cell encounters a tumor cell. APCs are produced at a constant rate λ, they
intake antigen and become loaded at rate α and die at rate δ1 . Loaded APCs die at
rate δ2 . We propose that the rate of activation of T cells is proportional to the ratio
psT D
). After the encounter of an inactivated
of positive to negative signals ( b1 βT C+b
2 sT D+n

T cell with loaded APCs, a positive signal is activated. This is represented by term
psT D in system (4.1). Immune checkpoints downregulate T cells proportionally to
the encounter of T cells and tumor cells and to the encounter of T cells and APCs, this
includes the pathways through which CTLA-4 and PD-1 activate. The parameters b1
and b2 represent the strength of the inhibitory signals and the parameter p represents
the strength of the positive signal. The rate of antigen presentation/reception is
represented by s and the rate at which the tumor cells impair the immune response
is represented by β. The parameter n represents an additional inhibitory pathway. T
cells die at a rate u. We estimate some parameter values from the literature, which
are based on studies of melanoma in mice. For those parameters for which there is
no estimate, we perform a sensitivity analysis over a parameter range that produces
biologically relevant values. The description and units of all parameters are in Table
4.1.
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4.2.2

Equilibria

We investigate the equilibrium points of the system (4.1) as a function of the negative
signals b1 and b2 , the positive signal p, and the rate of antigen reception s, which are
the parameters of interest in this investigation because they are the key parameters
in the activation/production of killer T cells. There are three biologically relevant
equilibrium points obtained by solving the system (4.1): the point

∗

∗

∗

∗

E1 = (C , A , D , T ) =




λ
0, , 0, 0
δ1

(4.2)

corresponds to immunity, an outcome in which tumor cells are cleared. It is straightforward to show that this equilibrium point is always locally unstable when the intrinsic growth rate of the tumor cells is positive (r > 0).
One of the outcomes in which tolerance of tumor cells is reached corresponds to
the saturation of tumor cells and the disappearance of T cells:


αk
λ
λ
∗
∗
∗
∗
,
,0
E2 = (C , A , D , T ) = k,
αk + δ1 δ2 αk + δ1

(4.3)

This equilibrium point is stable if
D∗ =

αk
λ
un
<
δ2 αk + δ1
ps

(4.4)

This condition implies that saturation of tumor cells is stable if the number of
loaded APCs remains below a threshold which increases for a small costimulatory
signal p and a small rate of antigen presentation/reception s.
The other equilibrium points are the solution of a cubic equation (E.4). For
more details about the equilibrium points and stability see appendix E. From our
simulations, we obtain only one more biologically relevant equilibrium point, in which
tumor cells lie between C ∗ = 0 and the carrying capacity C ∗ = k, we name it E3.
The existence and stability of E3 and whether E3 corresponds to saturation of tumor
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cells, an intermediate value of tumor cells or immunity depends on the parameter
combinations considered.

4.2.3

Initial conditions

We investigate the role of initial conditions during an immune response in the presence
of costimulatory and inhibitory signals. We start by varying the initial tumor size
and compare the tumor dynamics for different values of the inhibitory signals b1 and
b2 while the positive signal p is fixed. Then, we vary the initial number of loaded
APCs to simulate how dendritic cell vaccination impacts the immune response in
the presence of costimulatory and negative signals. Lastly, we investigate how the
initial number of activated T cells affects the tumor dynamics in the presence of
costimulatory and inhibitory signals.

4.2.4

Sensitivity analysis

We perform a sensitivity analysis in which we simultaneously vary the following key
parameters of the model: the net growth rate of tumor cells, r, the killing rate of tumor
cells, γ, the rate of antigen intake, α, the rate of antigen reception, s, the negative
signals, b1 and b2 , the positive signal, p, and the strength of additional inhibitory
pathways, n. We perform 5000 simulations using latin hypercube sampling within
uniform parameter ranges in a logarithmic scale that produce biologically relevant
outcomes (see table 4.1). All simulations are performed in MATLAB and Statistics
Toolbox Release 2014a, The MathWorks, Inc., Natick, Massachusetts, United States.
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Table 4.1: Model parameters

Notation

Description

Value, Units
Reference

r

Net growth rate of tumor cells
Carrying capacity of tumor cells
Killing rate when a T
cell encounters a tumor
cell
Rate of production of
dendritic cells
Rate of antigen uptake
Death rate of dendritic
cells
Death rate of loaded
dendritic cells
Death rate of T cells
Strength of positive signal
Strength of inhibitory
signal proportional to
encounter of dendritic
and T cells
Strength of inhibitory
signal proportional to
encounter of tumor and
T cells
Rate of antigen reception
Rate at which tumor
cells impair T cells
Additional inhibitory
signal

0.3954 day−1 [93]

k
γ

λ
α
δ1
δ2
u
p
b1

b2

s
β
n

and

Range
for
Sensitivity
Analysis
[10−6 , 1]

109 cells [93]
8 × 10−3 cell−1 day−1 ,
assumed
2.4388 × 104 cell day−1
[93]
varies, cell−1 day−1
0.2310 day−1 [99]

[10−3 , 1]

[10−9 , 1]

0.2310 day−1 [99]
0.1199 day−1 [99]
varies, cell day−1

[10−3 , 1]

varies, dimensionless

[10−8 , 1]

varies, dimensionless

[10−8 , 1]

varies, cell−1 day−1

[10−5 , 1]

9.42 × 10−12 cell−1 day−1
[100]
1 cell day−1 , assumed

[10−1 , 10]
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4.3

Results

4.3.1

Immune response dynamics at equilibrium

Equilibria as a function of positive and negative signals
The equilibrium point E1, corresponding to immunity, is unstable (for r > 0) and
exists for all values of the strength of costimulatory and negative signals. The equilibrium point E2, representing saturation of tumor cells, also exists for all values of
the costimulatory and inhibitory signals, and its stability does not depend on b1 and
b2 (see equation (4.4)). Therefore, we restrict our investigation to the equilibrium E3,
which is the equilibrium value where the number of tumor cells lie between immunity
and saturation and whose stability does depend on the inhibitory signals (b1 and b2 ),
as well as the rate of antigen reception s, and the costimulatory signal p, among other
parameters.
First, we investigate the strength of the negative signal activated after a T cell
encounters a tumor cell (b1 ) and the strength of the negative signal activated after an
APC presents antigen to T cells (b2 ). In figure 4.2(a), we vary the negative signals
b1 and b2 , while the positive signal p is fixed at p = 0.1. As b1 and b2 increase and
cross a threshold, tumor cells approach their carrying capacity (figure 4.2(a)). In the
parameter region explored, we observe that E3 is unstable for small values of b1 and b2 .
As b1 and b2 increase and cross a threshold, E3 becomes stable. Note that the effect
of b1 on the number of tumor cells is smaller compared to b2 , which is explained by
the assumption that tumor cells impair T cells at a very low rate, β = 9.42 × 10−12 .
In the parameter regions investigated in figure 4.2(a), the equilibrium point E2 is
unstable.
In figure 4.2(b) we vary the positive signal p while b1 = b2 . By doing this, we
study how tumor cells corresponding to E3 vary as function of the positive and
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(b)

(a)

Figure 4.2: Bifurcation diagrams illustrating the number of tumor cells at the equilibrium point E3 as a function of the negative signals b1 , b2 and the positive signal p.
The orange and green regions represent the parameter values for which the equilibrium point E3 is stable and unstable, respectively. (a) Varying the negative signals
b1 and b2 while p = 0.1, s = 2 × 10−5 , α = 10−5 . (b) Varying the positive signal p
while b1 = b2 and s = 10−3 , α = 10−9 . The rest of the parameter values are fixed, see
table 4.1.
negative signals, simultaneously. The equilibrium value E3 decreases as we increase
the positive signal p (figure 4.2(b)) when both negative signals b1 and b2 are relatively
small. Once b1 = b2 increases and crosses a threshold, tumor cells reach values close
to their carrying capacity despite high values of p. A similar behavior occurs for
stability; E3 is stable provided that b1 = b2 is relatively high.

The rate of antigen presentation/reception and b2
In figure 4.3, we plot a bifurcation diagram of the equilibrium point E3, as a function
of the rate of antigen presentation/reception s and the strength b2 of the inhibitory
pathway which activates proportional to s and the encounter of T and loaded APCs.
We remark that E3 can get values close to E1 and coincides with E2 depending on
the parameter combinations considered. We set b1 = 0 and p = 1, so that we can
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Figure 4.3: Bifurcation diagram of the number of tumor cells corresponding to the
equilibrium point E3 lying between saturation and immunity, as a function of the
rate of antigen reception s and the inhibitory signal b2 . The orange and green regions
represent the parameter values for which the equilibrium point E3 is stable and
unstable, respectively. Parameters used: b1 = 0, p = 1, α = 10−9 . The rest of the
parameter values are described in table 4.1.
study the joint effect of s and the negative signal b2 .
We observe that when s is near zero, tumor cells reach high values even for a small
inhibitory signal b2 . As s increases, tumor cells remain at intermediate numbers as
long as the inhibitory signal b2 remains below a threshold. Interestingly, as b2 increases
and crosses a threshold, the number of tumor cells increases approaching saturation
very quickly, despite a relatively high rate of antigen reception (figure 4.3). Once
b2 increases and crosses a threshold, the equilibrium E3 becomes stable. Thus, the
stimulation of antigen presentation/reception becomes ineffective if the strength of
an inhibitory pathway that activates after the encounter of loaded APCs and T cells
is relatively high.
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4.3.2

Dynamics of immune responses as a function of negative and positive signals

We investigate the effects of the costimulatory and inhibitory signals on the type
of immunologic responses observed under different scenarios. The initial conditions
are taken as follows: (C, A, D, T ) = (106 , 104 , 10, 10). We assume that initially, the
number of loaded dendritic cells and activated T cells are small compared to the
initial tumor size. In section 4.3.3 we further examine the role of initial conditions
during an immunologic response to cancer.

How do costimulatory and inhibitory signals shape an immunologic response?
Here, we fix the strength of the positive signal p and examine the temporal dynamics
as we vary the strength of the negative signals b1 and b2 . If the inhibitory signals
are weak (so that immune checkpoints inhibit T cell activation partially) there is an
immune response and the tumor cell population is reduced, then the tumor population
grows again, is reduced and the pattern repeats with time (figure 4.4(a)). Tumor cells
oscillate and the period of these oscillations increases as we decrease the strength of
the negative signals b1 and b2 , meaning that tumor cells can remain at small number
for longer time periods as long as the inhibitory signals remain small. If we increase
the negative signals b1 and b2 , the number of cancer cells exhibit damped oscillations
that eventually reach high or intermediate values (figure 4.4(b)). If we consider a
larger value of the negative signals b1 and b2 , cancer cells approach saturation very
quickly (figure 4.4(c)). T cells remain at very small numbers when the negative signals
are large. Thus, a positive signal is effective as long as the negative signals are small
enough, i.e, the immune checkpoints must be blocked in order to clear tumor cells.
Notice that in figure 4.4, tumor cells show stable oscillations or tumor cells approach
their carrying capacity, which corresponds to a stable equilibrium. This is related
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(a) b1 = 0.005, b2 = 0.005

(b) b1 = 0.01, b2 = 0.01

(c) b1 = 0.1, b2 = 0.1

Figure 4.4: The effect of increasing negative signals on the temporal dynamics of
tumor and immune cells. In (a) b1 = b2 = 0.005; (b) b1 = b2 = 0.01; (c) b1 = b2 =
0.1. The initial population sizes are C(0) = 106 , A(0) = 104 , D(0) = 10, T (0) =
10. Parameters used: p = 0.1, s = 10−3 , α = 10−9 . In all panels, the green line
corresponds to loaded dendritic cells, the blue line corresponds to T cells, and the
black line corresponds to tumor cells. The rest of the parameter values are described
in table 4.1.
to the results in section 4.3.1, where we find stable equilibrium points for relatively
high values of the strength of the negative signals. As the negative signals decrease,
it is possible to find unstable oscillatory solutions, as observed when we investigated
the temporal dynamics for smaller values of b1 and b2 , and under different initial
conditions (see section 4.3.3).
The observations above are also confirmed when we investigate the value of the
first peak of tumor cells, the time it takes tumor cells to reach the first peak and the
value of the maximum peak of tumor cells as a function of the inhibitory signals b1 and
b2 in the time interval [0, 400] days. When the inhibitory signals are small, the value
of the first and the maximum peaks of tumor cells are relatively small compared to
the high inhibitory signals (figure 4.5, center and bottom panels). Notice that when
b2 is high, tumor cells reach values close to saturation independently of the value
of b1 , while for b1 tumor cells reach values close to saturation as long as b2 is also
high. As explained earlier, we are assuming that tumor cells impair T cells at a very
low rate, β = 9.24 × 10−12 , which diminishes the effect of the negative signal with
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Figure 4.5: The first peak, the time to reach the first peak and the maximum peak
as a function of the negative signals b1 and b2 . The time interval is [0, 400] days. The
initial population sizes are C(0) = 106 , A(0) = 104 , D(0) = 10, T (0) = 10 and the
parameters used are p = 0.1, s = 10−3 , α = 10−9 . The rest of parameter values are
described in table 4.1.
strength b1 . In figure 4.4 above, we only observed stable solutions. If we consider
smaller values of the negative signals as we did in figure 4.5, we also observe that the
maximum peak of tumor cells is a non monotonic function of the negative signals,
indicating the existence of unstable oscillatory solutions. These oscillatory solutions
are also observed in section 4.3.3 where we investigated the role of initial conditions.
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4.3.3

The role of initial conditions

In this section, we explore the effects of assuming different initial values of tumor
cells, loaded APCs and T cells with varying values of the strengths of costimulatory
and inhibitory signals. Overall, we find that the initial sizes of these cell populations
alter only the transient dynamics of the immune response, indicating that the signals
involved in the activation/downregulation of T cells are more determinant in shaping
the long-term immune response to cancer.

Tumor size
We investigate the impact of different initial tumor sizes for different values of the
negative and positive signals. In figure 4.6 we consider five different initial tumor
sizes while we vary the negative signals b1 and b2 . Under the action of negative and
costimulatory signals, different initial tumor sizes have a similar qualitative behavior.
If the negative signals are relatively high and the initial T cell population is small
T (0) = 10, tumor cells saturate very quickly or remain at an intermediate value for
all initial tumor sizes considered (figure 4.6(a), top and center panel). When the
negative signals are smaller, tumor cells grow initially, but as time increases they are
“cleared out” during a long time period (figure 4.6(a), bottom panel). Tumor cells
are not fully eliminated, and eventually they will peak again, but as a long as the
inhibitory signals remain small, they will not be able to saturate or remain at high
numbers.
In figure 4.6(b), we plot the time it takes the number of tumor cells to reach the
first peak, the value at the first peak and the maximum value of the peak of tumor
cells observed in the time interval [0, 400] days, as a function of the negative signal b2
while b1 = 10−4 . We observe that the value of the first peak of tumor cells increases
as we increase the negative signal b2 for all initial tumor sizes considered (figure
4.6(b), center panel), together with the time to reach the first peak (figure 4.6(b),
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Figure 4.6: Varying the initial tumor size. (a) The top panels, the center panels, and the
bottom panels correspond to b1 = b2 = 0.5, b1 = b2 = 0.01 and b1 = b2 = 10−4 , respectively.
(b) The top panel, the center panel and the bottom panel correspond to the time to reach
the first peak, the first peak and the maximum peak of tumor cells, respectively, as a
function of the negative signal b2 while b1 = 10−4 . The time interval is [0, 400] days. The
initial number of APCs, loaded APCs and T cells are A(0) = 104 , D(0) = 10, T (0) = 10,
respectively. Parameters used: p = 0.05, s = 10−3 , α = 10−9 . The rest of the parameter
values are described in table 4.1.

top panel). Small initial tumor sizes take longer to reach the first peak (figure 4.6(b),
top panel). In general, the maximum peak of tumor cells increases as b2 increases,
although for small values of b2 , tumor cells can reach large values indicating that
even a low inhibitory signal can lead to a high number of tumor cells. Increasing the
initial number of tumor cells alters the transient dynamics of the immune response.
However, whether the response is sustained is controlled by the signals involved.
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Figure 4.7: Varying the initial number of loaded dendritic cells. (a) The top panels, the
center panels and the bottom panels correspond to b1 = b2 = 0.5, b1 = b2 = 0.01 and
b1 = b2 = 10−4 , respectively. (b) The top panel, the center panel and the bottom panel
correspond to the time to reach the first peak, the first peak and the maximum peak,
respectively, as a function of the negative signal b2 while b1 = 10−4 . The time interval is
[0, 400] days. The initial number of tumor cells, APCs and T cells are C(0) = 106 , A(0) =
104 , T (0) = 10, respectively. Parameters used: p = 0.05, s = 10−3 , α = 10−9 . The rest of
parameter values are described in table 4.1.

Varying the initial number of loaded APCs
Antigen presenting cells are able to present antigen to T cells so that T cells activate
and kill tumor cells. In figure 4.7, we study 5 different values for the initial number
of loaded APCs while we vary the inhibitory signals b1 and b2 . If the negative signals
are relatively high, increasing the number of APCs has no effect; tumor cells reach
saturation very quickly or remain at intermediate values (figure 4.7(a), top and center
panels). When the negative signals are smaller, even a small number of initial loaded
APCs can help to maintain tumor cells at small numbers for long time periods (figure
4.7(a), bottom panel).
In figure 4.7(b), we plot the time it takes for tumor cells to reach the first peak,
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the value of the first peak and the value of the maximum peak of tumor cells in the
time interval [0, 400] days as a function of the negative signal b2 while b1 = 10−4 . The
value of the first peak and the time to reach the first peak increase as b2 increases
(figure 4.7(b), top and center panels); the time to reach the first peak is longer for a
larger initial number of loaded APCs. We observe that as b2 increases and reaches a
threshold, all initial numbers of APCs reach similar values for the first peak and the
maximum peak of tumor cells (figure 4.7(b), center and bottom panels).
Thus, increasing the initial number of APCs helps to maintain tumor cells at
small numbers if the inhibitory signals are small. This is important because it suggests
that immunotherapy via dendritic cell vaccination is successful as long as the immune
checkpoints are successfully blocked. We remark that under the presence of inhibitory
signals, increasing the initial number of dendritic cells is able to modify the transient
dynamics of the immune response. The final outcome of the immune response is
ultimately controlled by the different signals activating and downregulating T cells.

Initial count of activated T cells
We investigate 5 values of the initial number of T cells for different values of the negative signals while the positive signal p is fixed. When the strength of the negative
signals is relatively high, the outcome is saturation or tumor cells reach an intermediate value (figure 4.8(a), top and center panels). We observe that a larger initial
number of T cells delays the time for tumor cells to reach saturation or an intermediate value. When the strength of the negative signals are smaller, even a relatively
small number of T cells is able to maintain tumor cells at very small numbers for long
periods of time (figure 4.8(a), bottom panel).
When we examine the first peak of tumor cells and the time to reach it, we find
that a relatively large initial number of T cells significantly delays the time to reach
the first peak, which holds independently of the value of the inhibitory signal b2
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Figure 4.8: Varying the initial number of T cells. (a) The top panel, the center panel
and the bottom panels correspond to b1 = b2 = 0.5, b1 = b2 = 0.01 and b1 = b2 = 10−4 ,
respectively. (b) The top panel, the center panel and the bottom panel correspond to
the time to reach the first peak, the first peak and the maximum peak of tumor cells,
respectively, as a function of the negative signal b2 while b1 = 10−4 . The time interval
is [0, 400] days. Parameters used: p = 0.05, s = 10−3 , α = 10−9 . The rest of parameter
values are described in table 4.1. The remaining initial populations are C(0) = 106 , A(0) =
104 , D(0) = 10.

(figure 4.8(b), top panel), in fact, for the largest value of the initial number of T cells
considered, T (0) = 3 × 103 , a peak was not observed in the parameter region explored
in the time interval [0, 400] days. For small values of b2 , a small initial number of T
cells can reach the highest peak; as b2 increases, tumor cells reach a similar value of
the highest peak for all initial values of T cells considered.
Therefore, an effective immunologic response is more likely if the initial count of
activated T cells is relatively large. In fact, when the inhibitory signals are small,
tumor cells can be cleared for long time periods, which could mean an increase in
survival times of a patient with cancer. This reveals the role of the absolute T
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lymphocyte count as a bio marker associated with immunotherapy success.

4.4

Assessing parameter uncertainty

We perform a sensitivity analysis in which we simultaneously vary the key parameters
of the model. Specifically, we vary the net growth rate of tumor cells r, the killing
rate of tumor cells γ, the rate of antigen intake α, the rate of antigen reception s,
the strength of the negative signals b1 and b2 , the strength of the positive signal p,
and the strength of the additional inhibitory signals n. We perform 5000 calculations
using latin hypercube sampling. The parameter ranges are given in table 4.1.
In figure 4.9, we plot the resulting distribution of the number of tumor cells at
equilibrium E3, which lies between immunity and saturation (it can reach saturation
(E2) and values close to immunity (E1), as observed before). We investigate combinations of parameter sets that produced biologically relevant outcomes (non-negative
number of cells). Approximately 32% of these parameter combinations resulted in
a number of tumor cells below one, and only 6% resulted in values above 108 , so
there is approximately 62% percent of intermediate values. We found that 80% of
the simulations producing biologically relevant outcomes resulted in an unstable equilibrium, and thus, 20% in a stable one. Most of the unstable solutions correspond
to an intermediate or a small number of tumor cells. In addition, we find that all
values above 108 are stable, indicating that once the tumor reaches high values, it
will remain there. We also mention that 15% of the 5000 parameter sets produced a
number of tumor cells greater than their carrying capacity, which is associated with
the lowest values of the positive signal p and the rate of antigen reception s. These
simulations were not considered given that they correspond to a negative number of
T cells.
Overall, we observe that if we allow all important parameters in the model to
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Figure 4.9: Sensitivity analysis. Histogram of the number of tumor cells for the
equilibrium value E3. We simultaneously vary the net growth rate of the tumor, r,
the killing rate of tumor cells, γ, the rate of antigen intake, α, the rate of antigen
reception, s, the strength of the negative signals, b1 and b2 , the positive signal, p, and
the strength of additional inhibitory signals, n. The parameter ranges and the values
of the fixed parameters are presented in table 4.1.
vary in a broad range, the number of tumor cells at equilibrium E3 varies from small
values (immunity), through intermediate values to values close to saturation. Most
of the intermediate and small values of tumor cells are unstable, while all values close
to saturation are stable.

4.5

Discussion

We propose a model that describes the role of antigen presentation, costimulatory
(positive) signals, and inhibitory (negative) signals during the activation of T cells
capable of killing tumor cells. There are two key differences between the model
presented here and most of the previous work that has modeled an immunologic
response to cancer. First, we assume that tumor cells are not the only cells capable of
impairing an immunologic response. Thus, we include a term in which the encounter
of APCs with T cells also activates an immune checkpoint. Second, we propose that
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killer T cells increase at a rate determined by a balance between positive and negative
signals, so that the regulatory feedback upregulates or downregulates the activation
of new killer T cells.
We find that the relative strength of positive and negative signals plays a crucial
role when triggering T cells to fight tumor cells. When the strength of the costimulatory signal is low, we observe that even a low inhibitory signal can lead to tumor
cells remaining at relatively large numbers. This is consistent with the finding that
the stimulation of molecules providing positive signals for T cell activation is crucial in the modulation of an immune response [63, 101–104]. When the strength of
the costimulatory signal is high enough, T cells are able to trigger and sustain an
immunologic response, but this depends on the strength of the inhibitory signals,
because tumor cells can remain at high numbers when the inhibitory pathways are
also high. Therefore, if a positive signal is maintained and the inhibitory pathways
are successfully blocked, T cells can trigger and sustain an immunologic response,
which is consistent with the increasing survival rates achieved by blocking immune
checkpoints [68, 70, 105–109].
T cells require antigen presentation to activate. The question is how much antigen presentation is optimal given that an inhibitory pathway activates after APCs
present antigen to T cells. We observe that increasing the rate of antigen reception
is not effective when the strength of this inhibitory pathway is high. This might
explain why immunotherapy via stimulation of antigen receptor signaling can fail in
sustaining an immunologic response to cancer over longer time periods. Our finding
agrees with Sharma and Allison who suggest that over-stimulation of antigen reception signaling might be counter-productive to T cell activation if it is administered
when the immune checkpoints are activated [98]. This challenges one of the premises
under which antigen stimulation is currently deployed, and suggests that stimulation
of antigen reception and blockade of immune checkpoints can be more effective if both
are targeted simultaneously.
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In addition, we studied the role of the initial sizes of immune and tumor cells
on the dynamics of the immunologic response. Specifically, we investigated dendritic cell vaccination (DCV) by varying the initial number of loaded APCs. We
found that DCV has an effect on the transient dynamics of an immune response if
it is administered when the strength of the inhibitory signals is low. This suggests
that immunotherapy via DCV can be successful if immune checkpoints are blocked,
otherwise, DCV could be counterproductive because it will enhance the strength of
the inhibitory pathway initiated after the antigen presentation by dendritic cells to
T cells. The initial count of activated T cells also plays an important role in the
transient dynamics of an immune response. We found that a relatively large initial
number of activated T cells can significantly delay tumor cell growth, even in the
presence of inhibitory signals. In fact, when the inhibitory signals are low, a small
initial number of activated T cells can keep tumor cells at very small numbers. This
is consistent with findings from clinical studies that the absolute lymphocyte count
is a positive biomarker associated with longer survival rates during immune checkpoint blockade [69, 110]. Overall, varying the initial number of tumor, dendritic and
T cells altered only the transient dynamics of the immune response, indicating that
costimulatory and inhibitory signals are the key determinants for the final outcome
of an immunologic response against cancer.
Finally, we discuss the limitations and potential extensions of our model. In our
study, we used parameter estimates from melanoma in mice (for those parameters
for which there is information in the literature, see table 4.1 for more details). The
appropriate time scale is days, which would likely be different for data from human
patients because many biological processes occur faster in mice than in humans. In
order to account for the uncertainty in the model parameters, which could reflect
tumor and patient variability, we perform a sensitivity analysis. This analysis lead to
a variety of outcomes: from a small number of tumor cells, to intermediate values and
finally tumor cells reaching their carrying capacity. Particularly, we notice that when
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tumor cells reach high numbers close to saturation, the equilibrium E3 was stable,
which indicates that once tumor cells reach high numbers, they will remain there.
When we investigated the temporal dynamics of immune responses for small values
of the strength of the negative signals b1 and b2 , in certain scenarios we observed that
tumor cells oscillated between high and very small values. Perhaps, in a stochastic
framework, once tumor cells reach very small values, these scenarios would correspond
to full clearance of tumor cells which is not captured in our deterministic model. This
reveals the need for stochastic models that can capture other features of an immune
response against cancer, which are not observed under a deterministic framework. Our
model does not include all types of immune cells in an attempt to keep the model
analysis tractable, but it does include the main interactions between tumor cells and
immune cells. In practice, the success of an immunologic response to cancer depends
on other factors and it varies from patient to patient and between tumor types. The
expression of bio markers in addition to the absolute T lymphocyte count, might be
important to investigate. It has been suggested that the T cell receptor repertoire is
an important bio marker that could be associated with immunotherapy success [111].
Overall, our model offers potential explanations as to why some immunotherapy
treatments cannot sustain an immunologic response to cancer; it suggests that immunotherapy treatments that stimulate antigen reception signaling (up to a certain
rate) can maintain a response for longer time periods if the immune checkpoints are
blocked. Overstimulation might be counterproductive if the immune checkpoints are
activated.
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Conclusions
We have used mathematical modeling to gain insight into key mechanisms that shape
cancer dynamics. In chapter 2, we derived a compartmental model of homeostatic
cell renewal in hierarchical tissues described by a system of differential equations,
which predicts the expected number of mutants in each compartment by adding the
contributions of different chains of differentiation observed while a number of mature
cells is discarded in the top of the hierarchy. This allowed us to investigate the role of
different proliferation patterns and tissue architecture in the accumulation of one-hit
mutants. Overall, we find that if the optimization task is to delay the accumulation
of one-hit mutants, short chains of differentiation are better in the long run; on the
other hand, if the optimization task is to delay the time to observe a second-hit
mutant, long chains of differentiation are preferred, which is a more realistic measure
of cancer risk, given that for some cancers two mutations could be enough to initiate
a tumor. In chapter 3 we extend the model proposed in chapter 2 by adding a fitness
advantage/disadvantage to mutants. We find that the hierarchical tissue acts as a
suppressor of selection during homeostatic cell renewal. In addition, we found that the
combination of an increasing architecture and long chains of differentiation provides
a robust strategy when it comes to delaying the time to observe a second-hit mutant.
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Particularly, we found that increasing the stem cell pool could decrease the time to
observe a second-hit mutant, which can translate into a higher risk of cancer.
Finally, we proposed a model of an immune response to cancer where we show
the key role of costimulatory and inhibitory signals. The model allowed us to investigate different immunotherapy treatments and to study under which conditions
immunotherapy could succeed/fail. Overall, we find that treatments based on stimulation of antigen reception signaling could be counterproductive if they are administered
when the immune checkpoints (inhibitory signals) are not blocked.

80

Appendices

A Further analysis of the deterministic mutant dynamics

82

B Comparison of the ODEs and stochastic simulations for large systems

86

C Further notes on the role of the compartment size

88

D Further notes on tissue architecture, division patterns and fitness

93

E Equilibria and stability for the immune response model

97

81

Appendix A
Further analysis of the
deterministic mutant dynamics
Here we provide some analysis of the large mutation rate, large population regime
(N u  1). We investigate the total number of mutants as a function of the proliferation probability v. As time increases, the total number of mutants decays with
v (figure A.1) but for some times, the total number of mutants is a non-monotonic
function of v. We observe that small values of the proliferation probability and values close to one produce the largest number of mutants. This might be explained
by the fact that when v is small, cell division occurs in more compartments due to
longer chains of differentiation, and thus, more compartments get saturated with mutants, which becomes a permanent state of the system. For large values of v, the
division activity is concentrated in a single top compartment or in a small number
of top compartments with relatively large population sizes which leads to the rapid
accumulation of mutants in the top part of the tissue. These dynamics are transient
because as time increases the remaining compartments saturate, thus, small values
will eventually produce more mutants.
It appears that there is an optimal value of the proliferation probability v that
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Figure A.1: The total number of mutants as a function of the proliferation probability v from the ODE approximation. The total population size is assumed to
be 1, 111, 000 cells, the mutation rate is u = 10−3 , and n = 3 (four compartments). We compare the following architectures: increasing compartment sizes
(N0 = 103 , N1 = 104 , N2 = 105 , N3 = 106 , corresponds to the blue line), equal popuTotal Population
= 277750, i = 0, . . . , 3, corresponds to the black
lation sizes (Ni =
4
line), and decreasing compartment sizes (N0 = 106 , N1 = 105 , N2 = 104 , N3 = 103 ,
corresponds to the green line). We plot the total number of mutants as a function of
the proliferation probability v at different times.
delays the accumulation of mutations and it seems to be time dependent. We observe
that as time increases, the optimal value of v is shifting toward an intermediate or
higher value, figure A.1.
In figure A.1, we further investigate three types of tissue architecture as a function
of the proliferation probability. We find that a scenario of 4 compartments with
populations decreasing from compartment Cn to the stem cell compartment (N0 =
103 , N1 = 104 , N2 = 105 , N3 = 106 ), accumulated more mutants than a scenario
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Figure A.2: The ODE mutant dynamics for 4 compartments, under two architectures.
Blue lines correspond to increasing compartment size: N0 = 40, N1 = 80, N2 =
120, N3 = 160, and green lines to the decreasing compartment sizes, N0 = 160, N1 =
120, N2 = 80, N3 = 40. The compartments are labeled C1 , . . . , C4 to the left of the
lines. The other parameters are v = 0.1 and u = 0.1.
of 4 compartments with equal population sizes (Ni = 277750, i = 0, . . . , 3) or a
scenario where the population sizes decrease from the stem cell compartment to the
compartment with mature cells (N0 = 106 , N1 = 105 , N2 = 104 , N3 = 103 ). This
dynamic is transient because the systems eventually reach the same steady-state
value, as observed in figure A.2.
Figure A.2 shows details of mutant accumulation dynamics for two opposing tissue
architectures: increasing compartmental sizes (blue) and decreasing compartmental
sizes (green). One can see that at first, the linear growth of mutants in each compartment is the same for both models; the stem cell compartment has the smallest
number of mutants while the mature compartment has the largest because of the
larger number of divisions in that compartment. Later on, however, differences in
the behavior of the two architecture types appear. In the system where the compartment size increases from the stem cell compartment to the mature cell compartment
(blue), the smallest compartment is the most “protected” (has fewer divisions), and
the largest compartment has the easiest time accumulating mutations, therefore such

84

Appendix A. Further analysis of the deterministic mutant dynamics

a system is relatively efficient in mutation accumulation. In the opposite case (green),
the largest number of mutations has to accumulate in the most protected (stem cell)
compartment, and this naturally takes longer. While at the steady state, both systems have the same number of mutations, the transient behavior is characterized by
a smaller number of mutations in the architecture where compartment size increases
from Cn to C0 .
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Comparison of the ODEs and
stochastic simulations for large
systems
The stochastic and deterministic models coincide in the regime where uN  1, as
demonstrated in figure B.1. We compare the expected number of mutants predicted
by the ODEs with the mean number of mutants obtained from the simulations in
a deterministic regime and found that they both predict the qualitative behavior of
the model very well. The comparison was made for a scenario with 4 compartments
where the population sizes increase from the stem cell compartment to the fully
differentiated cell compartment (N0 = 103 , N1 = 104 , N2 = 105 , N3 = 106 ).
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Figure B.1: Comparison between the average number of mutants from 1000 stochastic simulations without replacement and the expected number of mutants predicted by the ODE
approximation. (a) Comparing the number of mutants for a high value of the proliferation
probability, v = 0.9. (b) Comparing the number of mutants when the proliferation probability is small, v = 0.1. Solid lines correspond to the number of mutants in compartment
Ci , i = 1, . . . , 3, predicted by the ODE approximation (Ci ODE v = 0.1, for small v and Ci
ODE v = 0.9 for high v) and dashed lines correspond to the mean number of mutants in
compartment Ci from the stochastic simulations (Ci SIM v = 0.1, for small v and Ci SIM
v = 0.9 for high v). We assume n = 3, a mutation rate of u = 10−1 , and the compartment
sizes are N0 = 103 , N1 = 104 , N2 = 105 , N3 = 106 .
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Further notes on the role of the
compartment size
In section 2.3.4, v and the compartment sizes are assumed independent, which might
be an over-simplification. Suppose that a number of cells differentiated out of the Ck
compartment. Then compartments Ck and Ck−1 might “compete” to fill the empty
spaces. It is possible that compartment Ck is small and Ck−1 is large (and crowded?).
In this case, differentiations from Ck−1 to Ck are preferred, and the probability of
proliferation, vk , is relatively low. One possibility is to set vk = Nk /(Nk + Nk−1 ), or,
more generally,
v0 = 1,

vk =

Nkβ
β
Nkβ + Nk−1

,

1 ≤ k ≤ n − 1,

vn = 0.

(C.1)

Again, the optimization task is to arrange the populations in the different compartments to minimize mutation production. Figure C.1 illustrates some of the patterns
we have observed. It compares two opposite arrangements of compartment sizes, increasing from N0 to Nn (blue lines), and decreasing from N0 to Nn (yellow lines). In
the example provided, the increase or decrease is exponential, but other laws have also
been investigated and give qualitatively similar results. According to formula (C.1),
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the increasing compartment architecture leads to higher values of v than decreasing
architecture.
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Figure C.1: Comparison of mutant dynamics for two different compartment size arrangements: increasing compartment size Ni = 80ei+1 (blue lines), and decreasing
compartment size Ni = 80e5−i (yellow lines), for 0 ≤ i ≤ n = 4, m0 = 0.1. The rare
mutation limit is assumed. The probability of proliferation in each compartment, vk ,
is determined by equation (C.1), where (a) β = 1, (b) β = 3, and (c) β = 5. The
values of vk are shown in the leftmost plots. The conditional probability that a mutant is generated in each compartment (given that a mutant is generated) is plotted
in the middle graphs. The rightmost graphs show the relative number of mutants in
both systems as functions of time. Note that these graphs can only be interpreted
for purposes of comparison, not as absolute numbers.

Consider an extreme scenario where β → ∞ in (C.1). If the compartment size
grows from C0 to Cn , we have vk = 1 for 0 ≤ k ≤ n − 1, and only trees of length 1
exist. If the compartment size decreases from C0 to Cn , we have vk = 0 for 1 ≤ k ≤ n,
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and all the trees have length n.
For increasing compartment sizes, mutants can only appear in compartment Cn−1 ,
and they fixate with probability m0 /Nn−1 (where m0 is the initial number of mutants),
such that the expected colony size is given by m0 . For decreasing sizes, mutants can
appear in all compartments, but they are flushed out from any compartment except
from C0 , where they fixate with probability 1/N0 . So, only mutants that originate in
C0 can give rise to fixation in the state
n−1
m0 X
Nk .
N0 k=0

(C.2)

The probability that a mutation occurs in compartment C0 (given that a mutation
occurs) is
1+

1
Pn−2
i=0

2i

= 21−n .

(C.3)

The product of factors (C.2) and (C.3) defines the long time behavior of the
mutant numbers for the decreasing compartment sizes in figure C.1, as β increases.
In the limit where β → ∞, the increasing compartment system is characterized by a
constant (and equal to m0 ) number of mutants.
Finally, for completeness, we present stochastic simulations addressing the differences between the behavior of increasing and decreasing architecture structures. In
figure C.2, one-hit mutants are studied. This figure shows the same trends as figure 2.7, where increasing and constant architectures are compared; in figure 2.7, the
differences are more pronounced.
Figure C.3 studies two-hit mutant generation, and includes increasing and decreasing architectures. It should be compared with figure 2.8 (increasing and constant
architectures). Again, the same trends are observed, but the differences are larger in
the case of figure C.3.
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Figure C.2: Mean number of mutants from 1000 stochastic simulations. We compare two arrangements of the compartment sizes: decreasing from C0 to C3 (N0 =
120, N1 = 80, N2 = 40, N3 = 20) and increasing from C0 to C3 (N0 = 20, N1 =
40, N2 = 80, N3 = 120). (a) The mean number of mutants produced in compartments C0 , C1 , C2 and C3 for v = 0.9 (b) The mean number of mutants produced in
compartments C0 , C1 , C2 and C3 for v = 0.1. (c) The mean of the total number of
mutants comparing both architectures for v = 0.9 (blue line) and v = 0.1 (green line).
For all panels, solid lines correspond to decreasing architecture and dashed lines to
increasing architecture. We assume n = 3 and u = 0.001.
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Figure C.3: Distribution of the time to observe a second mutation from 5000 stochastic simulations. We consider two arrangements of the compartment sizes: decreasing
from C0 to C3 (N0 = 120, N1 = 80, N2 = 40, N3 = 20) and increasing from C0 to C3
(N0 = 20, N1 = 40, N2 = 80, N3 = 120). (a) The time to observe a second mutant
for both architectures and a high value of the proliferation probability, v = 0.9. The
mean time for decreasing and increasing architectures is 3.32 and 3.41 respectively
(p < 0.001). (b) The time to observe a second mutant for both architectures and a
small value of the proliferation probability, v = 0.1. The mean time for decreasing
and increasing architectures is 3.73 and 3.51 respectively (p < 0.001). (c) The time
to observe a second mutant for a decreasing architecture for both small and high v.
We assume n = 3, u = 0.001.
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Further notes on tissue
architecture, division patterns and
fitness
We observe in the stochastic simulations that advantageous and disadvantageous
one-hit mutants reached similar numbers when a decreasing architecture was investigated, with disadvantageous mutations accumulating slightly more mutants, specially
for high values of v (figure D.1(b)). This is similar to what we observed when we use
the ODE approximation for large systems, see figure 3.1. For small v, all types of
mutations reached identical numbers (figure D.1(a)). Clearly, a decreasing architecture accumulates less mutants than an increasing architecture, similar to what was
observed for the ODE approximation (figure 3.1).
For second-hit mutants, increasing architecture did better delaying the time for
second-hit mutant compared to either constant or decreasing architecture for short
chains of differentiation (high values of v). In figure D.2 we compare increasing and
constant architectures. We find that for small values of v (panels c and d), constant is
better than increasing architecture for both advantageous and disadvantageous mu-
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Figure D.1: The mean of the total number of mutants that occur in increasing versus
decreasing architectures for different fitness values, based on 1000 stochastic simulations. (a) Increasing architecture (N0 = 20, N1 = 40, N2 = 80, N3 = 120, solid lines)
versus decreasing architecture (N0 = 120, N1 = 80, N2 = 40, N3 = 20, dashed lines),
for small values of v and 2 values of the fitness parameter r. (b) Same as in (a) but
for a high value of v. The mutation rate is u = 10−3 and n = 3.
tants. For advantageous mutants, the mean times to a two-hit mutant for constant
and increasing architectures are 3.6798 and 3.5929, respectively, and for deleterious
mutants, the mean times for constant and increasing architectures are 3.6945 and
3.5948, respectively. For both panels, figure D.2(c,d), the p-value is less than 0.05,
which means that there is a significant difference in the mean times to observe a
second-hit mutant. Conversely, for high values of v, increasing architecture is better
than constant architecture only for advantageous mutations (figure D.2(a): the mean
times to a two-hit mutant for constant and increasing architectures are 3.3690 and
3.3953, respectively). For disadvantageous mutants there is no significant difference,
(figure D.2(b), p = 0.9235).

94

Appendix D. Further notes on tissue architecture, division patterns and fitness

A similar result was observed when we compared increasing and decreasing architectures. In this scenario, increasing was better than decreasing only for high values
of v for both advantageous and disadvantageous mutants (figure D.3). High values of
v can lead to hyperproliferation of cells, which can be a dangerous scenario. In this
context, an increasing architecture does a better job delaying the time to a second
mutation for high values of v and advantageous mutations. This can be interpreted
as an optimal evolutionary strategy to minimize cancer risk when differentiation is
lost.

Figure D.2: Comparing increasing and constant architectures for advantageous and
disadvantageous mutants. Distribution of the time to observe a second mutation from
5000 stochastic simulations. (a) and (b) Comparing increasing and constant architectures for high v and advantageous and disadvantageous mutants, respectively. (c) and
(d) Comparing increasing and constant architectures for small v and advantageous
and disadvantageous mutants, respectively. For constant architecture, the compartment sizes are N0 = 65, N1 = 65, N2 = 65, N3 = 65 and for increasing architecture,
N0 = 20, N1 = 40, N2 = 80, N3 = 120. The mutation rate is u = 10−3 and n = 3.
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Figure D.3: Comparing increasing and decreasing architectures for advantageous and
disadvantageous mutants. Distribution of the time to observe a second mutation
from 5000 stochastic simulations. (a) and (b) Comparing increasing and decreasing
architectures for high v and advantageous and disadvantageous mutants, respectively.
(c) and (d) Comparing increasing and decreasing architectures for small v and advantageous and disadvantageous mutants, respectively. For decreasing architecture,
compartment sizes are N0 = 120, N1 = 80, N2 = 40, N3 = 20 and for increasing architecture, N0 = 20, N1 = 40, N2 = 80, N3 = 120. The mutation rate is u = 10−3 and
n = 3.
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Equilibria and stability for the
immune response model
The Jacobian of system (4.1) is given by




J =




r−

2rC
k

− γT

0

−γC

0

−αA

−αC − δ1

0

0

αA

αC

−δ2
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−psb1 βDT 2
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psnD
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−u

(E.1)

One of the equilibrium values obtained by setting system (4.1) equal to zero corresponds
to immunity, (C, A, D, T ) = (0, δλ1 , 0, 0). If we plug these values into equation (E.1), we
obtain


r



−α δλ
λ
1
J(0, , 0, 0) = 
 λ
δ1
 αδ
 1
0

0

0

−δ1

0

0

−δ2

0

0

0





0 
.

0 

−u

(E.2)

The eigenvalues of this matrix are the diagonal entries, therefore, the equilibrium value
corresponding to immunity is unstable if r > 0.
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The equilibrium value corresponding to saturation of tumor cells is given by
(C, A, D, T ) = (k,

αk
λ
λ
,
, 0).
αk + δ1 δ2 αk + δ1

If we plug these values into equation (E.1), we get



−r



λ
−α αk+δ
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0
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0
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(E.3)

The eigenvalues of this matrix are all negative except for the eigenvalue
e=

λ
ps αk
− u,
n δ2 αk + δ1

D=

αk
λ
un
<
.
δ2 αk + δ1
ps

which is negative if

This is the stability condition for the equilibrium point where tumor cells reach saturation.
The other equilibrium values are given by
λ
αλC
r
A=
,D =
,T =
αC + δ1
δ2 (αC + δ1 )
γ



C
1−
,
k

where C is a solution of the equation

f (C) =




ub1 βrα 3
ub2 srαλ ub1 βr
δ1
C +
−
α−
C 2+
γk
γδ2 k
γ
k


psαγ ub1 βrδ1 ub2 rαλ
−
−
− unα C − unδ1 = 0.
δ2
γ
γδ2

(E.4)

This is a cubic equation as a function of C and solutions are obtained numerically. The
function f (C) must always have at least one real positive solution because f (0) < 0 and f →
+∞ as C → ∞ (the coefficient of C 3 is positive for all positive values of the parameters).
The solution could be larger than k, in which case, T would be negative, which is not
biologically relevant. It is also straightforward to obtain conditions that guarantee the
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existence of a single real positive solution by inspecting the curvature of f . In general, if
f 00 (C) > 0 for all C ≥ 0, a single positive-valued solution always exists.
We find that
6ub1 βrα
f (C) =
C +2
γk
00



ub2 srαλ ub1 βr
−
γδ2 k
γ



δ1
α−
k

(E.5)

Given that the first term in equation E.5 is always positive or zero when C ≥ 0, one
condition that guarantees the existence of a single real positive solution occurs when the
constant term is greater than zero, which implies that
sb2 αλ − b1 βkαδ2 + b1 βδ1 δ2 > 0.
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